<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName A++V2.4.dtd?>
<?SourceDTD.Version 2.4?>
<?ConverterInfo.XSLTName springer2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">Commun Biol</journal-id>
    <journal-id journal-id-type="iso-abbrev">Commun Biol</journal-id>
    <journal-title-group>
      <journal-title>Communications Biology</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2399-3642</issn>
    <publisher>
      <publisher-name>Nature Publishing Group UK</publisher-name>
      <publisher-loc>London</publisher-loc>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">9411158</article-id>
    <article-id pub-id-type="publisher-id">3816</article-id>
    <article-id pub-id-type="doi">10.1038/s42003-022-03816-9</article-id>
    <article-categories>
      <subj-group subj-group-type="heading">
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>LeMeDISCO is a computational method for large-scale prediction &amp; molecular interpretation of disease comorbidity</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Astore</surname>
          <given-names>Courtney</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author" equal-contrib="yes">
        <name>
          <surname>Zhou</surname>
          <given-names>Hongyi</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Ilkowski</surname>
          <given-names>Bartosz</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author">
        <name>
          <surname>Forness</surname>
          <given-names>Jessica</given-names>
        </name>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <contrib contrib-type="author" corresp="yes">
        <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-1877-4958</contrib-id>
        <name>
          <surname>Skolnick</surname>
          <given-names>Jeffrey</given-names>
        </name>
        <address>
          <email>skolnick@gatech.edu</email>
        </address>
        <xref ref-type="aff" rid="Aff1"/>
      </contrib>
      <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.213917.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2097 4943</institution-id><institution>Center for the Study of Systems Biology, School of Biological Sciences, </institution><institution>Georgia Institute of Technology, </institution></institution-wrap>Atlanta, GA 30332 USA </aff>
    </contrib-group>
    <pub-date pub-type="epub">
      <day>25</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="pmc-release">
      <day>25</day>
      <month>8</month>
      <year>2022</year>
    </pub-date>
    <pub-date pub-type="collection">
      <year>2022</year>
    </pub-date>
    <volume>5</volume>
    <elocation-id>870</elocation-id>
    <history>
      <date date-type="received">
        <day>30</day>
        <month>9</month>
        <year>2021</year>
      </date>
      <date date-type="accepted">
        <day>8</day>
        <month>8</month>
        <year>2022</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© The Author(s) 2022</copyright-statement>
      <license>
        <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
        <license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p>
      </license>
    </permissions>
    <abstract id="Abs1">
      <p id="Par1">To understand the origin of disease comorbidity and to identify the essential proteins and pathways underlying comorbid diseases, we developed <bold>LeMeDISCO</bold> (<bold>L</bold>arge-Scal<bold>e M</bold>olecular Int<bold>e</bold>rpretation of <bold>Dis</bold>ease <bold>Co</bold>morbidity), an algorithm that predicts disease comorbidities from shared mode of action proteins predicted by the artificial intelligence-based <bold>MEDICASCY</bold> algorithm. <bold>LeMeDISCO</bold> was applied to predict the occurrence of comorbid diseases for 3608 distinct diseases. Benchmarking shows that <bold>LeMeDISCO</bold> has much better comorbidity recall than the two molecular methods XD-score (44.5% vs. 6.4%) and the S<sub>AB</sub> score (68.6% vs. 8.0%). Its performance is somewhat comparable to the phenotype method-based Symptom Similarity Score, 63.7% vs. 100%, but <bold>LeMeDISCO</bold> works for far more cases and its large comorbidity recall is attributed to shared proteins that can help provide an understanding of the molecular mechanism(s) underlying disease comorbidity. The <bold>LeMeDISCO</bold> web server is available for academic users at: <ext-link ext-link-type="uri" xlink:href="http://sites.gatech.edu/cssb/LeMeDISCO">http://sites.gatech.edu/cssb/LeMeDISCO</ext-link>.</p>
    </abstract>
    <abstract id="Abs2" abstract-type="web-summary">
      <p id="Par2">LeMeDISCO predicts disease comorbidities and the proteins and pathways responsible for comorbidity, validated in ovarian cancer and coronary heart disease.</p>
    </abstract>
    <kwd-group kwd-group-type="npg-subject">
      <title>Subject terms</title>
      <kwd>Computational biology and bioinformatics</kwd>
      <kwd>Translational research</kwd>
    </kwd-group>
    <funding-group>
      <award-group>
        <funding-source>
          <institution>The Division of General Medical Sciences of the NIH, R35GM118039</institution>
        </funding-source>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>issue-copyright-statement</meta-name>
        <meta-value>© The Author(s) 2022</meta-value>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="Sec1" sec-type="introduction">
    <title>Introduction</title>
    <p id="Par3">Of the total of 3,634,743 disease pairs involving 13,034 distinct diseases in clinical data from 13,039,018 individuals<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, 78.8% involving all 13,034 diseases have a larger than random probability that they co-occur in one individual. Disease comorbidity, the co-occurrence of distinct diseases in one individual, is an interesting medical phenomenon, and it is important to understand their molecular origins. For example, rheumatoid arthritis, autoimmune thyroiditis, and insulin-dependent diabetes mellitus co-occur, but rheumatoid arthritis and multiple sclerosis do not<sup><xref ref-type="bibr" rid="CR2">2</xref></sup>. Previously, there have been several efforts to investigate the molecular features responsible for human disease comorbidities<sup><xref ref-type="bibr" rid="CR3">3</xref>–<xref ref-type="bibr" rid="CR9">9</xref></sup>. Some studies focused on particular subsets of diseases<sup><xref ref-type="bibr" rid="CR4">4</xref></sup> or ethnic groups, while others investigated the entire human disease network<sup><xref ref-type="bibr" rid="CR5">5</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup>. For example, ref. <sup><xref ref-type="bibr" rid="CR6">6</xref></sup> applied text mining to search the literature for disease-symptom associations. They then predicted the entire human disease–disease network based on a calculated symptom similarity score. While this approach covers many human diseases, it relies on prior knowledge of symptomatic information; this limits its disease coverage and only explains one phenotype (disease) by another phenotype (symptom). ref. <sup><xref ref-type="bibr" rid="CR7">7</xref></sup> utilized known disease–gene associations from GWAS<sup><xref ref-type="bibr" rid="CR10">10</xref></sup> and OMIM combined with a protein–protein interaction network to identify connected disease–gene clusters or modules. Another study also utilized known disease–gene associations and protein–protein interaction networks to characterize disease–disease relationships without requiring gene clusters<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>; thus, its disease coverage is better than in ref. <sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. These studies that used known disease–gene associations are limited by data availability. Indeed, only a small fraction of diseases have known associated genes. For example, ref. <sup><xref ref-type="bibr" rid="CR8">8</xref></sup> only covers 1022 of the 8043 diseases in the Disease Ontology database<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, with just 6594 pairs of diseases having a non-zero number of shared genes. Similarly, ref. <sup><xref ref-type="bibr" rid="CR7">7</xref></sup> found that about 59% of 44,551 disease pairs do not share genes and their relationship cannot be resolved based on the shared gene hypothesis. The effect of possibly missed proteins arising from both direct and indirect protein–protein interactions with known interacting proteins are accounted for by the network propagation method in the XD-score<sup><xref ref-type="bibr" rid="CR8">8</xref></sup> or by the disease module and network distance of the S<sub>AB</sub> score<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. However, those scores only marginally improve the recall rate of disease pairs that are clinically comorbid compared to that of shared genes in their methods (&lt;10% recall rate by both the XD-score and S<sub>AB</sub> score).</p>
    <p id="Par4">To address these limitations of existing studies, we developed <bold>LeMeDISCO</bold>, which extends our recently developed <bold>MEDICASCY</bold> machine learning approach<sup><xref ref-type="bibr" rid="CR12">12</xref></sup> for predicting disease indications and mode of action (MOA) proteins (as well as small molecule drug side effects and efficacy) to predict disease comorbidities and the proteins and pathways responsible for their comorbidity. <bold>LeMeDISCO</bold> covers 6.5 million pairs of diseases compared to 97,666 pairs by the XD-score<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, 44,551 pairs by the S<sub>AB</sub> score<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and 133,107 pairs by the Symptom Similarity Score<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. Assuming that the most enriched comorbid proteins are responsible for disease comorbidity, we determine the most frequent comorbidity enriched MOA proteins. These proteins are then employed in pathway analysis<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. As examples, we predict the comorbid diseases, comorbidity enriched MOA proteins, and pathways associated with coronary artery disease (CAD) and ovarian cancer (OC). We note that recently machine learning (ML) methods have been successfully employed in numerous areas of biology<sup><xref ref-type="bibr" rid="CR12">12</xref>,<xref ref-type="bibr" rid="CR14">14</xref>–<xref ref-type="bibr" rid="CR16">16</xref></sup>. However, due to MLs “black box” nature, it is not easy to trace back the biological meaning of the predictions and the molecular origin(s) of disease comorbidity. Thus, as in previous works<sup><xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup>, we adopt an explicit score that provides a set of common proteins responsible for comorbidity predictions.</p>
  </sec>
  <sec id="Sec2" sec-type="results">
    <title>Results</title>
    <sec id="Sec3">
      <title>Benchmarking results of LeMeDISCO</title>
      <p id="Par5">To assess its relative performance, we compared the results of <bold>LeMeDISCO</bold> to three other methods, the XD-score<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>, the S<sub>AB</sub> score<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, and the Symptom Similarity Score<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. The XD-score was calculated as described in ref. <sup><xref ref-type="bibr" rid="CR8">8</xref></sup>: Using known disease–gene associations to create a vector representation of the disease by setting 1 for all associated genes and 0 for all others; then the vector was iteratively updated based on the Random Walk with Restart (RWR) algorithm, with a restart probability of <italic>p</italic> = 0.9 by using the STRING network database. Finally, the XD-score quantifying the relation of two diseases is defined using the updated vectors of two diseases. NG is the number of shared genes between disease pairs<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. The <italic>S</italic><sub><italic>AB</italic></sub> score, a protein–protein network-based separation of a disease pair calculated from known disease–gene associations is defined as S<sub>AB</sub> = &lt;d<sub>AB</sub>&gt;− (&lt;d<sub>AA</sub>&gt; +&lt;d<sub>BB</sub>&gt;)/2, where S<sub>AB</sub> compares the shortest distances between proteins within each disease A &amp; B<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, &lt;d<sub>AA</sub>&gt; and &lt;d<sub>BB</sub>&gt; , to the shortest distances &lt;d<sub>AB</sub> &gt; between A-B protein pairs<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. The Symptom Similarity Score was obtained by large scale text mining of the literature for disease-symptom relations represented as a vector, with the similarity score defined as the cosine similarity of the respective vectors<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In this work, a J-score for disease similarity is defined as the Jaccard index<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> of two diseases (see Method for details). The disease–disease relations of benchmarking data from Medicare insurance databases are quantified by their relative risk (RR) and φ<bold>-</bold>score (see Methods section for details)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The relative risk RR is defined in Eq. <xref rid="Equ6" ref-type="">4</xref>a and is the probability that two diseases occur in a single individual relative to random. The φ<bold>-</bold>score is the Pearson’s correlation for binary variables and is defined in Eq. <xref rid="Equ7" ref-type="">4</xref>b. Diseases in this work are represented by DOID numbers from the Human Disease Ontology database<sup><xref ref-type="bibr" rid="CR11">11</xref></sup>, and they are in clinical data usually denoted by ICD-9 or ICD-10 classifications<sup><xref ref-type="bibr" rid="CR18">18</xref></sup> or their Medical subject headings (MeSH) names<sup><xref ref-type="bibr" rid="CR19">19</xref></sup>.</p>
      <p id="Par6">Table <xref rid="Tab1" ref-type="table">1</xref> summarizes the results. We define a true positive comorbidity pair when their clinic log(RR) &gt;0, a predicted positive when XD-score &gt;0, <italic>S</italic><sub><italic>AB</italic></sub> score &lt;0, or the Symptom Similarity Score &gt;0.1 and <italic>q</italic> value &lt;0.05 for our J-score. Recall is defined as (the number of true positives having score &gt; cutoff or &lt; cutoff for <italic>S</italic><sub><italic>AB</italic></sub> score)/(total number of true positives). We emphasize that in calculating recall, the cutoffs are suggested by the respective work as being either biologically meaningful<sup><xref ref-type="bibr" rid="CR7">7</xref>,<xref ref-type="bibr" rid="CR8">8</xref></sup> or statistically significant<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. In addition to Pearson’s correlation coefficient (c.c.), recall and precision, the cutoff independent measures area under the receiver operating characteristic (AUROC) and the area under the precision-recall curve (AUPRC) are also compared.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Comparison of LeMeDISCO’s J-score with the XD-score, NG, <italic>S</italic><sub><italic>AB</italic></sub> score and Symptom Similarity Score for correlations with comorbidity quantified by the log(RR) score, φ<bold>-</bold>score, and recall<sup>a</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Log(RR) score</th><th>φ-score</th><th>Recall</th><th>Precision</th><th>AUROC</th><th>AUPRC</th></tr></thead><tbody><tr><td colspan="7"><italic>191,966 disease pairs</italic><sup><italic>b</italic></sup></td></tr><tr><td>LeMeDISCO</td><td><bold>0.116 (0.0)</bold></td><td><bold>0.090 (0.0)</bold></td><td><bold>37.1%</bold></td><td><bold>77.2%</bold></td><td><bold>0.528</bold></td><td><bold>0.780</bold></td></tr><tr><td>Permute drug–protein [<italic>p</italic> value]</td><td>0.050 ± 0.004 (0.0) [1.3 × 10<sup>−54</sup>]</td><td>0.060 ± 0.004 (0.0) [2.1 × 10<sup>−12</sup>]</td><td>8.8 ± 0.7% [2.0 × 10<sup>−315</sup>]</td><td>74.7 ± 1.3%[0.027]</td><td>0.495 ± 0.006 [3.5 × 10<sup>−9</sup>]</td><td>0.755 ± 0.004 [4.9 × 10<sup>−11</sup>]</td></tr><tr><td>Permute drug–disease [<italic>p</italic> value]</td><td>0.0026 ± 0.0056 (0.24) [4.0 × 10<sup>−92</sup>]</td><td>0.0029 ± 0.0075 (0.19) [1.2 × 10<sup>−31</sup>]</td><td>0.0137 ± 0.0828% [0.0]</td><td>54.3 ± 46.5% [0.31]</td><td>0.500 ± 0.001 [1.7 × 10<sup>−112</sup>]</td><td>0.757 ± 0.0006 [2.3 × 10<sup>−294</sup>]</td></tr><tr><td colspan="7"><italic>29,658 pairs</italic><sup><italic>c</italic></sup></td></tr><tr><td>LeMeDISCO</td><td><bold>0.146 (0.0)</bold></td><td><bold>0.106 (0.0)</bold></td><td><bold>44.5%</bold></td><td><bold>80.6%</bold></td><td><bold>0.531</bold></td><td><bold>0.812</bold></td></tr><tr><td>XD-score<sup><xref ref-type="bibr" rid="CR8">8</xref></sup></td><td>0.042 (2.8 × 10<sup>−13</sup>)</td><td>0.071 (9.7 × 10<sup>−35</sup>)</td><td>6.4%</td><td>77.8%</td><td>0.510</td><td>0.801</td></tr><tr><td>NG<sup>d</sup></td><td>0.0047 (0.42)</td><td>0.053 (6.6 × 10<sup>−20</sup>)</td><td>—</td><td>—</td><td>—</td><td>—</td></tr><tr><td colspan="7"><italic>943 disease pairs</italic><sup><italic>e</italic></sup></td></tr><tr><td>LeMeDISCO</td><td><bold>0.0986 (0.0024)</bold></td><td><bold>0.0886 (0.0065)</bold></td><td><bold>68.6%</bold></td><td>77.7%</td><td><bold>0.529</bold></td><td><bold>0.798</bold></td></tr><tr><td><italic>S</italic><sub><italic>AB</italic></sub> score<sup><xref ref-type="bibr" rid="CR7">7</xref></sup></td><td>−0.0620 (0.057)</td><td>−0.0413 (0.205)</td><td>8.0%</td><td><bold>85.3%</bold></td><td>0.434</td><td>0.761</td></tr><tr><td colspan="7"><italic>2621 disease pairs</italic><sup><italic>f</italic></sup></td></tr><tr><td>LeMeDISCO</td><td>0.140 (5.2 × 10<sup>−13</sup>)</td><td>0.135 (3.8 × 10<sup>−12</sup>)</td><td>63.7%</td><td>79.3%</td><td>0.512</td><td>0.814</td></tr><tr><td>Symptom similarity<sup><xref ref-type="bibr" rid="CR6">6</xref></sup></td><td><bold>0.322 (0.0)</bold></td><td><bold>0.194 (1.4</bold> × <bold>10</bold><sup><bold>−23</bold></sup><bold>)</bold></td><td><bold>100%</bold></td><td><bold>79.6%</bold></td><td><bold>0.587</bold></td><td><bold>0.856</bold></td></tr></tbody></table><table-wrap-foot><p><sup>a</sup>Numbers in parentheses “()” are the <italic>p</italic> values of the corresponding correlation. Bold indicates the best results for the given dataset. For the permutations of drug–protein and drug–disease relationships, the average ± standard deviation of 100 runs with different random seeds was given, the number in parenthesis “[]” is the <italic>p</italic> value converted from the <italic>z</italic>-score = (LeMeDISCO value-average)/standard deviation to characterize the statistical significance of the difference between LeMeDISCO and permutation tests.</p><p><sup>b</sup>Mapping the DOID IDs from the human DO database to ICD-9 IDs of ref. <sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, gives a set of 191,966 disease pairs.</p><p><sup>c</sup>Mapped the ICD-9 disease code to our DOID of DO and obtained a consensus subset of 29,658 disease pairs from Table 1’s dataset of 97,665 disease pairs in ref. <sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p><sup>d</sup>NG is the number of shared genes between disease pairs in ref. <sup><xref ref-type="bibr" rid="CR8">8</xref></sup>.</p><p><sup>e</sup>Consensus set of 943 disease pairs from the dataset of ref. <sup><xref ref-type="bibr" rid="CR7">7</xref></sup> and our dataset of 191,966.</p><p><sup>f</sup>A consensus dataset of 2621 disease pairs was obtained from their Supplementary dataset <xref rid="MOESM3" ref-type="media">4</xref> of ref. <sup><xref ref-type="bibr" rid="CR6">6</xref></sup> compared to our set of 191,966 pairs.</p></table-wrap-foot></table-wrap></p>
      <p id="Par7">Mapping the DOIDs to the ICD-9 ID classifications of ref. <sup><xref ref-type="bibr" rid="CR1">1</xref></sup>, excluding easy pairs when in the MEDICASCY library two diseases have <inline-formula id="IEq1"><alternatives><tex-math id="M1">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{shared\; \#\; of\; efficious\; drugs}}{\sqrt{{\#\; disease}1{efficious\; drugs}\times {\#\; disease}2{efficious\; drugs}}} \; &gt; \; 0.9$$\end{document}</tex-math><mml:math id="M2"><mml:mfrac><mml:mrow><mml:mi>s</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.16em"/><mml:mi>#</mml:mi><mml:mspace width="0.16em"/><mml:mi>o</mml:mi><mml:mi>f</mml:mi><mml:mspace width="0.16em"/><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.16em"/><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mi>#</mml:mi><mml:mspace width="0.16em"/><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mn>1</mml:mn><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.16em"/><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi><mml:mo>×</mml:mo><mml:mi>#</mml:mi><mml:mspace width="0.16em"/><mml:mi>d</mml:mi><mml:mi>i</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn><mml:mi>e</mml:mi><mml:mi>f</mml:mi><mml:mi>f</mml:mi><mml:mi>i</mml:mi><mml:mi>c</mml:mi><mml:mi>i</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mspace width="0.16em"/><mml:mi>d</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>g</mml:mi><mml:mi>s</mml:mi></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mspace width="0.16em"/><mml:mo>&gt;</mml:mo><mml:mspace width="0.16em"/><mml:mn>0.9</mml:mn></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq1.gif"/></alternatives></inline-formula>, we obtain 191,966 disease pairs for use in <bold>LeMeDISCO</bold> benchmarking. All Pearson’s correlations of the J-score with the log(RR) score (c.c. = 0.116, <italic>p</italic> value = 0) and φ<bold>-</bold>score (c.c. = 0.090, <italic>p</italic> value = 0) are statistically significant (<italic>p</italic> value &lt;0.05). The recall rate of J-score for this large set is 37.1%, and the AUROC of 0.528 is well better than random of 0.5.</p>
      <p id="Par8">The Permute drug–protein test has an average ± standard deviation from 100 runs 1958.6 ± 144.9 (54.3%) for diseases with non-zero MOA proteins. We note there are still significant correlations, though the absolute c.c. drops from 0.116 to 0.050 (<italic>p</italic> value = 0.0) for log(RR) and from 0.090 to 0.060 (<italic>p</italic> value = 0.0) for the φ<bold>-</bold>score, and the recall drops from 37.1% of true relationships to 8.8% due to that the number of diseases having correctly assigned MOA proteins drops to around half. All other measures are also worse. The <italic>p</italic> values of the difference between <bold>LeMeDISCO</bold> and this permutation test are significant for all measures (&lt;0.05).</p>
      <p id="Par9">On average, the Permute drug–disease test only has 55.09 (1.5%) diseases with non-zero MOAs. Its average recall of 0.0137% is much worse than that of the Permute drug–protein test because it loses the correct connections between diseases and proteins. Correlations with both log(RR) (c.c. = 0.0026, <italic>p</italic> value = 0.24) and the φ<bold>-</bold>score (c.c. = 0.0029, <italic>p</italic> value = 0.19) are insignificant. Except for precision, the <italic>p</italic> values of the difference between <bold>LeMeDISCO</bold> and this permutation test are all very significant (well below 0.05). The 54.3% average precision is due to its very few predictions (average only ~26). With these few predictions, a random selection of 26 pairs from the 191,966 (75.6% are true positives defined as log(RR) &gt;0) will have a probability of <inline-formula id="IEq2"><alternatives><tex-math id="M3">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\mathop{\sum }\nolimits_{k=14}^{26}{C}_{26}^{k}$$\end{document}</tex-math><mml:math id="M4"><mml:msubsup><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>14</mml:mn></mml:mrow><mml:mrow><mml:mn>26</mml:mn></mml:mrow></mml:msubsup><mml:msubsup><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mn>26</mml:mn></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq2.gif"/></alternatives></inline-formula> × 0.756<sup>k</sup> × 0.244<sup>26-k</sup> = 0.996 of having greater than 54.3% precision. This means the precision is not better than random selection.</p>
      <p id="Par10">To understand the significant difference between the Permute drug–protein and the Permute drug–disease tests, we note that MEDICASCY predicts drug–disease pairs based on two components: One uses the drug’s chemical structure to learn the indications of a drug from those drugs with similar structure. This component is insensitive to whether the drugs’ protein targets change. The other depends on the drug’s protein targets. In the Permute drug–protein test, a permuted drug–protein relation will randomly change the drug’s protein targets to another drug’s. MEDICASCY was applied after the permutation to ensure correct drug–disease relations. Thus, MEDICASCY’s prediction of drug–disease relations still has information from the permuted drug–protein relation and the disease-(through permuted drug)–protein relations are not completely lost. This actually reflects the fact that there are a subset of proteins that occur in many diseases and permuting the drug–protein relationship for this subset does not change the identification of proteins in a given disease. On the other hand, the permuted drug–disease test completely destroys the mapping of the protein (through the drug) to disease.</p>
      <p id="Par11">To compare <bold>LeMeDISCO</bold>’s J-score to the XD-score, we mapped their ICD-9 disease code to the DOIDs and obtained a subset of 29,658 pairs from their dataset of 97,665 pairs<sup><xref ref-type="bibr" rid="CR8">8</xref></sup>. As shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref> and Table <xref rid="Tab1" ref-type="table">1</xref>, the XD-score has a c.c. of 0.042 (<italic>p</italic> value = 2.8 × 10<sup>−13</sup>) with log(RR) and c.c. = 0.071 (<italic>p</italic> value = 9.7 × 10<sup>−35</sup>) with the φ<bold>-</bold>score. Their NG score (the number of shared genes) essentially has no significant correlation with log(RR) with a c.c. of 0.0047 (<italic>p</italic> value = 0.42) and only shows a correlation of 0.053 (<italic>p</italic> value = 6.6 × 10<sup>−20</sup>) with the φ<bold>-</bold>score. The J-score has much better correlations: c.c. = 0.146 (<italic>p</italic> value = 0.0) with log(RR), 0.106 (<italic>p</italic> value = 0.0) with the φ<bold>-</bold>score. The recall rate of the J-score is 44.5% compared to 6.4% for the XD-score. J-score’s precision (80.6 vs. 77.8%), AUROC (0.531 vs. 0.510), AUPRC (0.812 vs. 0.801) are all better. Supplementary Fig. <xref rid="MOESM1" ref-type="media">1</xref> shows distinct patterns of J-score and XD-score. The data points of the XD-score are mostly concentrated at an XD-score = 0, whereas those of the J-score spread across the full range of 0–1.</p>
      <p id="Par12">For comparison with the <italic>S</italic><sub><italic>AB</italic></sub> score<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, the MeSH<sup><xref ref-type="bibr" rid="CR19">19</xref></sup> disease names were mapped to their DOIDs. A consensus set of 943 disease pairs from their dataset and ours was obtained. As shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref> and Table <xref rid="Tab1" ref-type="table">1</xref>, compared to <italic>S</italic><sub><italic>AB</italic></sub><sup><xref ref-type="bibr" rid="CR7">7</xref></sup>, for the 947 disease pairs, <bold>LeMeDISCO</bold>’s J-score has a c.c. = 0.0986 (<italic>p</italic> value = 0.0024) with log(RR) and a c.c. = 0.0886 (<italic>p</italic> value = 0.0065) with the φ<bold>-</bold>score that are both better than those of the <italic>S</italic><sub><italic>AB</italic></sub> score with a c.c. = −0.0620 (<italic>p</italic> value = 0.057) with log(RR) and c.c. = −0.0413(<italic>p</italic> value = 0.205) with the φ<bold>-</bold>score; both are insignificant. The recall rate of the J-score is 68.6% and is an order of magnitude better than the 8.0% by the <italic>S</italic><sub><italic>AB</italic></sub> score when defining comorbid pairs when the <italic>S</italic><sub><italic>AB</italic></sub> score &lt;0; that is for a biologically meaningful disease–disease relationship<sup><xref ref-type="bibr" rid="CR7">7</xref></sup>. J-score has AUROC = 0.531 compared to <italic>S</italic><sub><italic>AB</italic></sub> score’s 0.434 that is even worse than random value 0.5 because its dominant <italic>S</italic><sub><italic>AB</italic></sub> score &gt;0 region is worse than random. The J-score also has a better AUPRC (0.798 vs. 0.761). However, J-score’s precision (77.7% vs. 85.3%) is slightly worse. Supplementary Fig. <xref rid="MOESM1" ref-type="media">2</xref> shows that the data points of the <italic>S</italic><sub><italic>AB</italic></sub> score are concentrated in the region <italic>S</italic><sub><italic>AB</italic></sub> &gt;0, whereas those of the J-score spread over the 0–1 region.</p>
      <p id="Par13">Next, a common dataset of 2621 disease pairs was obtained for comparison with the Symptom Similarity Score<sup><xref ref-type="bibr" rid="CR6">6</xref></sup>. As shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">3</xref> and Table <xref rid="Tab1" ref-type="table">1</xref>, the Symptom Similarity Score has better correlations of 0.322 (<italic>p</italic> value = 0.0) than 0.140 (<italic>p</italic> value = 5.2 × 10<sup>−13</sup>) by the J-score for the log(RR) and 0.194 (<italic>p</italic> value = 1.4 × 10<sup>−23</sup>) than 0.135 (<italic>p</italic> value = 3.8 × 10<sup>−12</sup>) by the J-score for the φ<bold>-</bold>score. It also has better recall (100 vs. 63.7%), AUROC (0.587 vs. 0.512) and AUPRC (0.856 vs. 0.814). However, the Symptom Similarity Score only explains the relationship of one phenotype (symptom) to another phenotype (disease). Nevertheless, all correlations of the J-score are statistically significant. The J-score’s precision is almost identical to that of the Symptom Similarity Score (79.3 vs. 79.6%). We note that Supplementary Figs. <xref rid="MOESM1" ref-type="media">3</xref>, <xref rid="MOESM1" ref-type="media">4</xref> show very similar patterns of the J-score and Symptom Similarity Score.</p>
    </sec>
    <sec id="Sec4">
      <title>MEDICASCY based MOA protein prediction</title>
      <p id="Par14">The ICD-10 main classification coverage of the 3608 diseases is shown in Fig. <xref rid="Fig1" ref-type="fig">1a</xref>. We first examine the number of predicted MOA proteins per indication from <bold>MEDICASCY</bold><sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. Using a <italic>q</italic> value cutoff of 0.05 and including protein isoforms, the average (median) number of MOA proteins per indication is 1,142.2 (339); the maximal and minimal values are 15,281 (almost half of the total 32,584 screened proteins) for mast cell sarcoma and 0 for 82 diseases. The histogram of the number of MOAs is shown in Fig. <xref rid="Fig1" ref-type="fig">1b</xref>. 71.0% (40.6%) of indications have &gt;100 (500) MOA proteins. These associations allowed us to expand the protein repertoire that might be associated with each disease and resemble the statistics from GWAS studies. Below, we describe the use of <bold>LeMeDISCO</bold> to predict disease comorbidities as well as prioritize these proteins.<fig id="Fig1"><label>Fig. 1</label><caption><title>Summary results for 3608 distinct diseases.</title><p><bold>a</bold> ICD-10 main classification coverage across the 3608 diseases. Some diseases are found in multiple groups; they were counted in each group with which they are associated. <bold>b</bold> Histogram of the number of MOAs. <bold>c</bold> Frequency (bin size 0.02) and density of the J-score for the ~2 million significant (<italic>q</italic> value &lt;0.05), non-redundant disease pairs. <bold>d</bold> Frequency (bin size = 100) and density of the degree (number of edges) of each disease (node). <bold>e</bold> Fraction of diseases in the giant component of disease–disease network versus the J-score cutoff.</p></caption><graphic xlink:href="42003_2022_3816_Fig1_HTML" id="d32e1521"/></fig></p>
    </sec>
    <sec id="Sec5">
      <title>Shared MOA proteins explain disease comorbidity by way of disease–disease relationships</title>
      <p id="Par15">We next examine the overall characteristics of the predicted comorbidity network of 3608 diseases. Eighty-two diseases do not have MOA protein predictions and thus do not have predicted comorbidities. There are a total of 6,507,028 possible pairwise disease associations. Of these, there are 2,137,022 significant pairwise disease associations (<italic>q</italic> value &lt;0.05) excluding the diagonals given by <bold>LeMeDISCO</bold>. Out of 3608, 3523 diseases have significant comorbidities. The density and frequency of the J-score for the significant non-redundant pairs is in Fig. <xref rid="Fig1" ref-type="fig">1c</xref>, and the density and frequency of the degree (number of edges) for each node (disease) is represented in Fig. <xref rid="Fig1" ref-type="fig">1d</xref>. Using a <italic>q</italic> value cutoff of 0.05, the average (median) number of comorbidities per disease is 608.3 (491). The largest (smallest) number of comorbidities is 2229 for Pneumonia aspiration and the smallest is 1 for these four diseases: glossopharyngeal neuralgia, median arcuate ligament syndrome, toxoplasmosis, hallucinogen dependence. The average closeness <inline-formula id="IEq3"><alternatives><tex-math id="M5">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\pm$$\end{document}</tex-math><mml:math id="M6"><mml:mo>±</mml:mo></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq3.gif"/></alternatives></inline-formula> one standard deviation (defined as the reciprocal of the shortest distance to all other nodes: <inline-formula id="IEq4"><alternatives><tex-math id="M7">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\frac{{{{{{{\mathrm{Number}}}}}}\; {{{{{\mathrm{of}}}}}}\; {{{{{\mathrm{other}}}}}}\; {{{{{\mathrm{nodes}}}}}}}}{\sum {{{{{{\mathrm{shortest}}}}}}\; {{{{{\mathrm{distance}}}}}}\; {{{{{\mathrm{to}}}}}}\; {{{{{\mathrm{other}}}}}}\; {{{{{\mathrm{nodes}}}}}}}}$$\end{document}</tex-math><mml:math id="M8"><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">Number</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">other</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">nodes</mml:mi></mml:mrow><mml:mrow><mml:mo>∑</mml:mo><mml:mi mathvariant="normal">shortest</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">distance</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">to</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">other</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">nodes</mml:mi></mml:mrow></mml:mfrac></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq4.gif"/></alternatives></inline-formula>) of all nodes is 0.535 ± 0.084, indicating that the majority of disease pairs have the shortest distance around 1/0.535. The average betweenness is 1135 ± 1727, i.e., on average, 1135 pairs of diseases have their shortest distance passing through the given disease node. Thus, the disease network is very dense.</p>
      <p id="Par16">The cumulative distribution for the J-score and <italic>q</italic> values for all of the comorbidities and the top 100 are shown in Supplementary Figs. <xref rid="MOESM1" ref-type="media">5</xref>, <xref rid="MOESM1" ref-type="media">6</xref>, respectively. The summary statistics of the scores for these thresholds are shown in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. What is clear from these figures and Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>, particularly for the top 100 ranked comorbidities, is that the 99.6% top-ranked 100 comorbidities have a <italic>q</italic> value &lt;0.005. In other words, while a <italic>q</italic> value threshold of 0.05 is used, in reality, the actual <italic>q</italic> values employed for subsequent analysis are far more significant.</p>
      <p id="Par17">Around 32.8% of the disease pairs have a <italic>q</italic> value &lt;0.05. This result is consistent with the 37.1% recall of large-scale benchmarking (see Table <xref rid="Tab1" ref-type="table">1</xref>). As shown in Fig. <xref rid="Fig1" ref-type="fig">1e</xref>, the giant component (GP) of the disease–disease network covers the entire network when the J-score is &lt;0.1 and the <italic>q</italic> value &lt;0.05, i.e., starting from any disease, one can walk to any other disease on the network. As the J-score cutoff increases, the number of diseases in the giant component decreases; however, the decrease is very slow. The rapid decrease only happens around a 0.45 J-score corresponding to an average <italic>q</italic> value of 1.63 × 10<sup>−6</sup> ± 1.81 × 10<sup>−4</sup>. Thus, the disease network is not only dense, but it is also strongly (i.e., one has to apply a high J-score cutoff to break the network into small GP) and highly significantly (compared to default <italic>q</italic> value 0.05) connected. These issues will be explored in future work.</p>
    </sec>
    <sec id="Sec6">
      <title>LeMeDISCO identified MOA proteins</title>
      <p id="Par18">In addition to the comorbidity predictions, <bold>LeMeDISCO</bold> also identifies comorbidity enriched MOA proteins. The comorbidity enriched MOA proteins are hierarchically ranked by their CoMOAenrich score (defined in the Methods section). Comparing the top 100 comorbidity enriched MOA proteins (hierarchically ranked by the CoMOAenrich score) with the <bold>MEDICASCY</bold> top 100 MOA proteins (ranked by <italic>q</italic> value), 92.5% of the diseases have proteins with a significant overlap <italic>p</italic> value (&lt;0.05). The cumulative distribution for the CoMOAenrich scores and <italic>q</italic> values for all the comorbidity enriched MOA proteins and the top 100 are shown in Supplementary Figs. <xref rid="MOESM1" ref-type="media">7,</xref><xref rid="MOESM1" ref-type="media"> 8</xref>, respectively. The summary statistics of the scores for these thresholds are shown in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. For the comorbidity enriched MOA proteins ranked by their CoMOAenrich score, 65.9% have a <italic>q</italic> value &lt;0.005. If one only assesses the top 100 comorbidity enriched MOA proteins, 67.1% have a <italic>q</italic> value &lt;0.005, which are the proteins used for the global pathway analysis.</p>
    </sec>
    <sec id="Sec7">
      <title>Mapping of the LeMeDISCO MOA proteins to significant pathways</title>
      <p id="Par19">The cumulative distribution of the <italic>q</italic> values for the pathways and the top 100 pathways are shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">9</xref> and the summary statistics are provided in Supplementary Table <xref rid="MOESM1" ref-type="media">1</xref>. As shown in Supplementary Fig. <xref rid="MOESM1" ref-type="media">9</xref>, 73.1% of the significant pathways (<italic>q</italic> value &lt;0.05) have a <italic>q</italic> value &lt;0.015. About 3453 or 95.7% of the 3608 diseases have significant pathways. We further note that there are some MOA proteins (e.g., AR, NR4A3, and PGR) and pathways (e.g., HSP90 chaperone cycle for steroid hormone receptors, SUMO E3 ligases SUMOylate target proteins, SUMOylation) that are present in approximately a third of the diseases in our library.</p>
    </sec>
    <sec id="Sec8">
      <title>Applications of LeMeDISCO</title>
      <p id="Par20">By way of illustration, we applied <bold>LeMeDISCO</bold> to two disparate diseases, coronary artery disease (CAD) and ovarian cancer (OC).</p>
    </sec>
    <sec id="Sec9">
      <title>Coronary artery disease (CAD)</title>
      <p id="Par21">CAD, a leading cause of death worldwide, is caused by narrowed or blocked arteries due to plaques composed of cholesterol or other fatty deposits lining the inner wall of the artery. These plaques result in decreased blood supply to the heart<sup><xref ref-type="bibr" rid="CR20">20</xref></sup>. We find 2576 significant comorbid diseases (<italic>q</italic> value &lt;0.05) and 785 (558) comorbidity enriched MOA proteins (genes) (score &gt;0.01), meaning that at least one of the top 100 comorbid disease shares the protein as an MOA protein. This is the <italic>p</italic> value weighted comorbidity frequency normalized by the number of comorbid diseases used for calculating the frequency. See Methods for more details. Forty-nine significant pathways (<italic>q</italic> value &lt;0.05) are associated with the top-ranked 100 comorbidity enriched proteins. The top 20 disease comorbidities, top 20 comorbidity enriched MOA proteins, and top 20 significant pathways are shown in Table <xref rid="Tab2" ref-type="table">2</xref>. There are several significant cardiovascular-related comorbidities such as heart disease, cardiovascular system disease, myocardial infarction, and congestive heart failure. Asthma<sup><xref ref-type="bibr" rid="CR21">21</xref></sup>, diabetes<sup><xref ref-type="bibr" rid="CR22">22</xref></sup>, and obstructive lung disease<sup><xref ref-type="bibr" rid="CR23">23</xref></sup> are also in the top ten with known comorbidities to CAD. CAD is also known to be comorbid with liver disease<sup><xref ref-type="bibr" rid="CR24">24</xref></sup>, kidney disease<sup><xref ref-type="bibr" rid="CR25">25</xref></sup>, and hyperthyroidism<sup><xref ref-type="bibr" rid="CR26">26</xref></sup>. Interestingly, allergic rhinitis is associated with decreased coronary heart disease<sup><xref ref-type="bibr" rid="CR27">27</xref></sup>. In summary, 14 (70%) of the top 20 predicted comorbid diseases have literature evidence to support these predictions. To further show that these comorbidities with literature evidence cannot be generated randomly, we randomly selected 20 diseases from the 3608 diseases and did a literature search for their associations with CAD. We found nine diseases, far fewer than our list of 14 diseases (see Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). A further random test selecting 20 from those after excluding LeMeDISCO predicted comorbid diseases to CAD, we find six diseases having literature evidence (see Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Top 20 comorbidities (excluding same disease pair, (i.e., CAD-CAD)), top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 pathways associated with the prediction CAD results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Comorbidities</th><th colspan="2">MOA proteins</th><th colspan="2">Pathways</th></tr><tr><th>Disease</th><th>J-score</th><th><italic>q</italic> value</th><th>Gene name</th><th>Score</th><th>Pathway</th><th><italic>q</italic> value</th></tr></thead><tbody><tr><td>Heart disease</td><td>0.47</td><td>&lt;0.0001</td><td>COX7A2L</td><td>0.38</td><td>Class A/1 (Rhodopsin-like receptors)</td><td>3.7 × 10<sup>−9</sup></td></tr><tr><td>Cardiovascular system disease</td><td>0.45</td><td>&lt;0.0001</td><td>COX7A2</td><td>0.38</td><td>Olfactory signaling pathway</td><td>2.7 × 10<sup>−8</sup></td></tr><tr><td>Obstructive lung disease</td><td>0.43</td><td>&lt;0.0001</td><td>COX7A1</td><td>0.38</td><td>GPCR ligand binding</td><td>3.8 × 10<sup>−8</sup></td></tr><tr><td>Asthma</td><td>0.44</td><td>&lt;0.0001</td><td>NR4A3</td><td>0.36</td><td>The canonical retinoid cycle in rods (twilight vision)</td><td>4.5 × 10<sup>−7</sup></td></tr><tr><td>Myocardial infarction</td><td>0.39</td><td>&lt;0.0001</td><td>PGR</td><td>0.36</td><td>ADORA2B mediated anti-inflammatory cytokines production</td><td>1.4 × 10<sup>−6</sup></td></tr><tr><td>Familial hyperlipidemia</td><td>0.33</td><td>&lt;0.0001</td><td>LXN</td><td>0.35</td><td>Nuclear receptor transcription pathway</td><td>2.3 × 10<sup>−6</sup></td></tr><tr><td>Diabetes mellitus</td><td>0.33</td><td>&lt;0.0001</td><td>OSBPL8</td><td>0.35</td><td>Anti-inflammatory response favoring Leishmania parasite infection</td><td>7.6 × 10<sup>−6</sup></td></tr><tr><td>Rhinitis</td><td>0.32</td><td>&lt;0.0001</td><td>SLC8A3</td><td>0.35</td><td>Leishmania parasite growth and survival</td><td>7.6 × 10<sup>−6</sup></td></tr><tr><td>Liver disease</td><td>0.31</td><td>&lt;0.0001</td><td>KCNA10</td><td>0.35</td><td>Peptide ligand-binding receptors</td><td>3.3 × 10<sup>−5</sup></td></tr><tr><td>Hyperthyroidism</td><td>0.31</td><td>&lt;0.0001</td><td>NR3C2</td><td>0.35</td><td>SUMOylation of intracellular receptors</td><td>3.5 × 10<sup>−5</sup></td></tr><tr><td>Chronic obstructive pulmonary disease</td><td>0.30</td><td>&lt;0.0001</td><td>RARRES1</td><td>0.35</td><td>G alpha (i) signaling events</td><td>9.7 × 10<sup>−5</sup></td></tr><tr><td>Lymphedema</td><td>0.29</td><td>&lt;0.0001</td><td>GPRC5A</td><td>0.34</td><td>Visual phototransduction</td><td>1.3 × 10<sup>−4</sup></td></tr><tr><td>Allergic asthma</td><td>0.29</td><td>&lt;0.0001</td><td>ANXA1</td><td>0.34</td><td>Amine ligand-binding receptors</td><td>1.5 × 10<sup>−4</sup></td></tr><tr><td>Intrinsic asthma</td><td>0.29</td><td>&lt;0.0001</td><td>NR3C1</td><td>0.33</td><td>Leishmania infection</td><td>1.6 × 10<sup>−4</sup></td></tr><tr><td>Pulmonary emphysema</td><td>0.29</td><td>&lt;0.0001</td><td>ELOVL7</td><td>0.33</td><td>Integrin cell surface interactions</td><td>3.6 × 10<sup>−4</sup></td></tr><tr><td>Syndrome</td><td>0.29</td><td>&lt;0.0001</td><td>TSPAN13</td><td>0.33</td><td>Sodium/Calcium exchangers</td><td>9.6 × 10<sup>−4</sup></td></tr><tr><td>Congestive heart failure</td><td>0.28</td><td>&lt;0.0001</td><td>GRP</td><td>0.33</td><td>Retinoid cycle disease events</td><td>9.7 × 10<sup>−4</sup></td></tr><tr><td>Kidney disease</td><td>0.28</td><td>&lt;0.0001</td><td>ELOVL3</td><td>0.33</td><td>Diseases associated with visual transduction</td><td>9.7 × 10<sup>−4</sup></td></tr><tr><td>pseudohypoparathyroidism</td><td>0.28</td><td>&lt;0.0001</td><td>ELOVL1</td><td>0.32</td><td>Reduction of cytosolic Ca++  levels</td><td>9.7 × 10<sup>−4</sup></td></tr><tr><td>Fatty liver disease</td><td>0.28</td><td>&lt;0.0001</td><td>OSBPL5</td><td>0.32</td><td>Diseases of the neuronal system</td><td>9.7 × 10<sup>−4</sup></td></tr></tbody></table></table-wrap></p>
      <p id="Par22">Among the top, COX-related comorbidity enriched proteins were found. COX proteins are involved in the synthesis of prostanoids. Prostanoids are structurally like lipids and are involved in thrombosis and other undesirable cardiovascular events<sup><xref ref-type="bibr" rid="CR28">28</xref></sup>. Several GPCR-related pathways (Class A/1 rhodopsin-like receptors, olfactory signaling pathway, GPCR ligand binding) are among the top five pathways predicted for CAD, consistent with the literature that GPCRs play a crucial role in heart function<sup><xref ref-type="bibr" rid="CR29">29</xref></sup>.</p>
      <p id="Par23">The above results were obtained without any extrinsic knowledge of CAD. Next, we show how <bold>LeMeDISCO</bold> can be used to prioritize targets from other studies. A GWAS study identified 155 CAD-associated genes<sup><xref ref-type="bibr" rid="CR30">30</xref></sup>. While they are associated with CAD, to find out which ones to target is a non-trivial task. Here, we applied <bold>LeMeDISCO</bold> to prioritize them by examining their frequencies of presence in other diseases. There were 26 comorbidity enriched MOA proteins (score &gt;0.01) and 40 pathways (<italic>p</italic> value &lt;0.05, but <italic>q</italic> value &lt;0.20) found from global pathway analysis of the 26 comorbidity enriched MOA proteins. The top disease comorbidities, top 20 comorbidity enriched MOA proteins, and top 20 pathways are shown in Table <xref rid="Tab3" ref-type="table">3</xref>. There were only three significant predicted comorbidities (<italic>q</italic> value &lt;0.05) by <bold>LeMeDISCO</bold>. The top two comorbidities are renal artery disease and anuria, both are associated with dysfunction of the kidneys and are related to CAD<sup><xref ref-type="bibr" rid="CR25">25</xref>,<xref ref-type="bibr" rid="CR31">31</xref></sup>. Anuria is attributed to failure of the kidneys to produce urine, and renal artery disease occurs when the arteries that supply blood and oxygen to the kidneys narrows. A study found an increase in renal artery stenosis in patients with CAD<sup><xref ref-type="bibr" rid="CR31">31</xref></sup>. The last comorbid disease is anterior uveitis. Studies showed that anterior uveitis is associated with Kawasaki disease that can lead to heart complication<sup><xref ref-type="bibr" rid="CR32">32</xref></sup>. Thus, all three have literature evidence.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Up to top 20 comorbidities, top 20 comorbidity enriched MOA proteins (with respect to input), and top 20 pathways (ranked by <italic>p</italic> value since <italic>q</italic> values are the same) associated with the prediction CAD GWAS-driven LeMeDISCO results using the gene set from ref. <sup><xref ref-type="bibr" rid="CR30">30</xref></sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Comorbidities</th><th colspan="2">MOA proteins</th><th colspan="3">Pathways</th></tr><tr><th>Disease</th><th>J-score</th><th><italic>q</italic> value</th><th>Gene name</th><th>Score</th><th>Pathway</th><th><italic>q</italic> value</th><th><italic>p</italic> value</th></tr></thead><tbody><tr><td>Renal artery disease</td><td>0.028</td><td>5.8 × 10<sup>−4</sup></td><td>PEX10</td><td>0.24</td><td>RAB geranylgeranylation</td><td>0.16</td><td>4.6 × 10<sup>−3</sup></td></tr><tr><td>Anuria</td><td>0.022</td><td>5.3 × 10<sup>−3</sup></td><td>BEND6</td><td>0.23</td><td>Platelet activation, signaling and aggregation</td><td>0.16</td><td>7.7 × 10<sup>−3</sup></td></tr><tr><td>Anterior uveitis</td><td>0.015</td><td>0.022</td><td>NEURL1</td><td>0.22</td><td>MET activates RAP1 and RAC1</td><td>0.16</td><td>0.017</td></tr><tr><td/><td/><td/><td>CCM2</td><td>0.20</td><td>RHO GTPases activate KTN1</td><td>0.16</td><td>0.017</td></tr><tr><td/><td/><td/><td>FGD6</td><td>0.20</td><td>Response to elevated platelet cytosolic Ca2+</td><td>0.16</td><td>0.019</td></tr><tr><td/><td/><td/><td>CENPW</td><td>0.20</td><td>Killing mechanisms</td><td>0.16</td><td>0.019</td></tr><tr><td/><td/><td/><td>PCID2</td><td>0.20</td><td>WNT5:FZD7-mediated leishmania damping</td><td>0.16</td><td>0.019</td></tr><tr><td/><td/><td/><td>RPL17</td><td>0.19</td><td>Diseases of signal transduction by growth factor receptors and second messengers</td><td>0.16</td><td>0.022</td></tr><tr><td/><td/><td/><td>MANEAL</td><td>0.18</td><td>PTK6 Regulates RHO GTPases, RAS GTPase, and MAP kinases</td><td>0.16</td><td>0.022</td></tr><tr><td/><td/><td/><td>HHAT</td><td>0.17</td><td>TFAP2 (AP-2) family regulates the transcription of growth factors and their receptors</td><td>0.16</td><td>0.024</td></tr><tr><td/><td/><td/><td>PHYHIP</td><td>0.16</td><td>Purine catabolism</td><td>0.16</td><td>0.030</td></tr><tr><td/><td/><td/><td>IYD</td><td>0.16</td><td>RHO GTPases activate CIT</td><td>0.16</td><td>0.031</td></tr><tr><td/><td/><td/><td>VEGFA</td><td>0.16</td><td>Signal transduction by L1</td><td>0.16</td><td>0.033</td></tr><tr><td/><td/><td/><td>HNRNPD</td><td>0.14</td><td>VEGFR2 mediated cell proliferation</td><td>0.16</td><td>0.033</td></tr><tr><td/><td/><td/><td>AGT</td><td>0.13</td><td>RHO GTPases Activate NADPH Oxidases</td><td>0.16</td><td>0.037</td></tr><tr><td/><td/><td/><td>PLEKHA1</td><td>0.12</td><td>RHO GTPases activate PAKs</td><td>0.16</td><td>0.037</td></tr><tr><td/><td/><td/><td>SERPINA1</td><td>0.11</td><td>TRAF6 mediated NF-kB activation</td><td>0.16</td><td>0.037</td></tr><tr><td/><td/><td/><td>NUDT5</td><td>0.04</td><td>Neutrophil degranulation</td><td>0.16</td><td>0.038</td></tr><tr><td/><td/><td/><td>RAB23</td><td>0.04</td><td>NOTCH3 Activation and Transmission of Signal to the Nucleus</td><td>0.16</td><td>0.039</td></tr><tr><td/><td/><td/><td>NKIRAS2</td><td>0.04</td><td>Signaling by NTRK2 (TRKB)</td><td>0.16</td><td>0.039</td></tr></tbody></table></table-wrap></p>
      <p id="Par24">While the top genes are associated with CAD according to the GWAS study of ref. <sup><xref ref-type="bibr" rid="CR30">30</xref></sup>, we predicted that they are also associated with the corresponding comorbid diseases—renal artery disease, anuria, and anterior uveitis. For example, VEGFA is predicted to be associated with all three comorbid diseases. It was found that in progressive kidney disease, the VEGFA expression level is attenuated<sup><xref ref-type="bibr" rid="CR33">33</xref></sup>; in contrast, in uveitis disease, it is increased<sup><xref ref-type="bibr" rid="CR34">34</xref></sup>. Other top genes are predicted to be associated only with anterior uveitis. Among them, SERPINA1 is a potential causal gene of uveitis<sup><xref ref-type="bibr" rid="CR35">35</xref></sup>, RAB23 is associated with uveitis in sarcoidosis<sup><xref ref-type="bibr" rid="CR36">36</xref></sup>, and HHAT has evidence of association with uveitis<sup><xref ref-type="bibr" rid="CR37">37</xref></sup>.</p>
      <p id="Par25">None of the 40 pathways obtained using the top 26 genes overlaps with the six pathways obtained using the original 155 genes with the same cutoff. The predicted top pathway RAB geranylgeranylation through RAB23/RAB5C genes is part of the signaling network of statin-induced effects of improving cardiac health in Drosophila<sup><xref ref-type="bibr" rid="CR38">38</xref></sup>.</p>
    </sec>
    <sec id="Sec10">
      <title>Ovarian cancer (OC)</title>
      <p id="Par26"><bold>LeMeDISCO</bold> predicts 1,092 significant comorbidities to OC (<italic>q</italic> value &lt;0.05), with 282 (171) comorbidity enriched MOA proteins (genes) (score &gt;0.01). There were 159 significant pathways (<italic>q</italic> value &lt;0.05) from the top 100 comorbidity enriched MOA proteins. The top 20 disease comorbidities, top 20 comorbidity enriched MOA proteins, and all significant pathways are shown in Table <xref rid="Tab4" ref-type="table">4</xref>. It is not surprising that all of the top comorbidities are cancers. The top first comorbid disease is testicular cancer. Although OC and testicular cancer cannot occur in one individual, they are hereditarily associated<sup><xref ref-type="bibr" rid="CR39">39</xref></sup>. Fallopian tube cancer is considered similar to OC. It was reported that squamous cell carcinoma occurred in the ovary<sup><xref ref-type="bibr" rid="CR40">40</xref></sup>. Nodular prostate, (the male version of OC), cervical cancer<sup><xref ref-type="bibr" rid="CR41">41</xref></sup>, and inflammatory breast carcinoma<sup><xref ref-type="bibr" rid="CR42">42</xref></sup> are all reproduction-related cancers like OC. OC from lung cancer metastasis occurs in 2–4% of OC patients<sup><xref ref-type="bibr" rid="CR43">43</xref></sup>. Bile duct cancer is a very rare site of OC metastases<sup><xref ref-type="bibr" rid="CR44">44</xref></sup>. Peritoneal cancer behaves similarly to OC. Gland cancer is linked to BRCA-positive families, and BRCA is a risk gene for ovarian cancer<sup><xref ref-type="bibr" rid="CR45">45</xref></sup>. Neurofibroma is reported to mimic ovarian tumors<sup><xref ref-type="bibr" rid="CR46">46</xref></sup>. Renal cell carcinoma is metastatic to ovarian and fallopian tube cancers<sup><xref ref-type="bibr" rid="CR47">47</xref></sup>. In total, 14 of the top 20 (70%) comorbidities have literature evidence. Similar to CAD, we did a literature search of 20 randomly selected diseases for their associations with OC. We found only 6 cases; far fewer than our 14 (see Supplementary Table <xref rid="MOESM1" ref-type="media">2</xref>). In a further random test selecting 20 from those after excluding <bold>LeMeDISCO</bold> predicted comorbid diseases to OC, we find four diseases have literature evidence (see Supplementary Table <xref rid="MOESM1" ref-type="media">3</xref>).<table-wrap id="Tab4"><label>Table 4</label><caption><p>Top 20 comorbidities (excluding same disease pair, (i.e., OC-OC)), top 20 comorbidity enriched MOA proteins (with respect to original disease), and top 20 pathways associated with the prediction OC results.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Comorbidities</th><th colspan="2">MOA proteins</th><th colspan="2">Pathways</th></tr><tr><th>Disease</th><th>J-score</th><th><italic>q</italic> value</th><th>Gene name</th><th>Score</th><th>Pathway</th><th><italic>q</italic> value</th></tr></thead><tbody><tr><td>testicular cancer</td><td>0.42</td><td>&lt;0.0001</td><td>TEK</td><td>0.5</td><td>MAPK1/MAPK3 signaling</td><td>7.10 × 10<sup>−15</sup></td></tr><tr><td>fallopian tube cancer</td><td>0.41</td><td>&lt;0.0001</td><td>TYRO3</td><td>0.49</td><td>EPH-Ephrin signaling</td><td>8.59 × 10<sup>−15</sup></td></tr><tr><td>squamous cell carcinoma</td><td>0.40</td><td>&lt;0.0001</td><td>RYK</td><td>0.49</td><td>RAF/MAP kinase cascade</td><td>2.37 × 10<sup>−14</sup></td></tr><tr><td>tongue squamous cell carcinoma</td><td>0.39</td><td>&lt;0.0001</td><td>MERTK</td><td>0.49</td><td>MAPK family signaling cascades</td><td>2.69 × 10<sup>−14</sup></td></tr><tr><td>nodular prostate</td><td>0.36</td><td>&lt;0.0001</td><td>AXL</td><td>0.49</td><td>FLT3 Signaling</td><td>3.83 × 10<sup>−14</sup></td></tr><tr><td>cervical cancer</td><td>0.36</td><td>&lt;0.0001</td><td>LTK</td><td>0.48</td><td>EPH-ephrin-mediated repulsion of cells</td><td>3.96 × 10<sup>−14</sup></td></tr><tr><td>myeloproliferative neoplasm</td><td>0.32</td><td>&lt;0.0001</td><td>EGFR</td><td>0.47</td><td>PI5P, PP2A, and IER3 Regulate PI3K/AKT Signaling</td><td>4.07 × 10<sup>−13</sup></td></tr><tr><td>inflammatory breast carcinoma</td><td>0.31</td><td>&lt;0.0001</td><td>KIT</td><td>0.47</td><td>Negative regulation of the PI3K/AKT network</td><td>9.15 × 10<sup>−13</sup></td></tr><tr><td>urinary bladder cancer</td><td>0.30</td><td>&lt;0.0001</td><td>KDR</td><td>0.47</td><td>Constitutive Signaling by Aberrant PI3K in Cancer</td><td>3.79 × 10<sup>−12</sup></td></tr><tr><td>lung cancer</td><td>0.30</td><td>&lt;0.0001</td><td>FLT3</td><td>0.47</td><td>PI3K/AKT Signaling in Cancer</td><td>1.3 × 10<sup>−10</sup></td></tr><tr><td>bile duct cancer</td><td>0.29</td><td>&lt;0.0001</td><td>FLT1</td><td>0.47</td><td>EPHA-mediated growth cone collapse</td><td>5.51 × 10<sup>−10</sup></td></tr><tr><td>parotid gland cancer</td><td>0.29</td><td>&lt;0.0001</td><td>ROR2</td><td>0.47</td><td>Diseases of signal transduction by growth factor receptors and second messengers</td><td>3.45 × 10<sup>−9</sup></td></tr><tr><td>neurofibroma</td><td>0.29</td><td>&lt;0.0001</td><td>RET</td><td>0.47</td><td>PIP3 activates AKT signaling</td><td>8.38 × 10<sup>−8</sup></td></tr><tr><td>peritoneum cancer</td><td>0.28</td><td>&lt;0.0001</td><td>PTK2B</td><td>0.47</td><td>EPHB-mediated forward signaling</td><td>2.83 × 10<sup>−7</sup></td></tr><tr><td>gallbladder cancer</td><td>0.28</td><td>&lt;0.0001</td><td>PTK2</td><td>0.47</td><td>Intracellular signaling by second messengers</td><td>4.76 × 10<sup>−7</sup></td></tr><tr><td>Barrett’s esophagus</td><td>0.28</td><td>&lt;0.0001</td><td>NTRK3</td><td>0.47</td><td>Toll-like receptor 4 (TLR4) cascade</td><td>4.87 × 10<sup>−6</sup></td></tr><tr><td>tongue cancer</td><td>0.27</td><td>&lt;0.0001</td><td>NTRK2</td><td>0.47</td><td>Toll-like receptor cascades</td><td>2.16 × 10<sup>−5</sup></td></tr><tr><td>larynx cancer</td><td>0.27</td><td>&lt;0.0001</td><td>NTRK1</td><td>0.47</td><td>ERBB2 activates PTK6 signaling</td><td>2.23 × 10<sup>−5</sup></td></tr><tr><td>kidney cancer</td><td>0.27</td><td>&lt;0.0001</td><td>MUSK</td><td>0.47</td><td>ERBB2 regulates cell motility</td><td>3.98 × 10<sup>−5</sup></td></tr><tr><td>lung benign neoplasm</td><td>0.27</td><td>&lt;0.0001</td><td>LMTK3</td><td>0.47</td><td>PI3K events in ERBB2 signaling</td><td>5.02 × 10<sup>−5</sup></td></tr></tbody></table></table-wrap></p>
      <p id="Par27">Eleven of the top 20 enriched MOA proteins are kinases that are cancer-related. The topmost comorbidity enriched MOA protein is TEK, angiopoietin-1 receptor; angiopoietins are found to promote ovarian cancer progression<sup><xref ref-type="bibr" rid="CR48">48</xref></sup>. Interestingly, TYRO3 is related to drug resistance in OC<sup><xref ref-type="bibr" rid="CR49">49</xref></sup>. The top predicted pathway by enriched MOAs is MAPK1/MAPK3 signaling that mediates the expression of ERBB2 silencing, OC cell migration, and invasion<sup><xref ref-type="bibr" rid="CR50">50</xref></sup>. There are also enriched pathways associated with ephrin ligands. Aggressive forms of ovarian cancer have been previously shown to involve upregulated forms of ephrin, such as ephrinA5<sup><xref ref-type="bibr" rid="CR51">51</xref></sup>. There are 14 ephrin-related comorbidity enriched MOA proteins found (all score &gt;0.37).</p>
      <p id="Par28">We next examined a set of 11 genes associated with OC risk from a study that assessed the multiple-gene germline sequences in 95,561 women with OC using <bold>LeMeDISCO</bold><sup><xref ref-type="bibr" rid="CR52">52</xref></sup>. The results for the top 20 comorbidities, seven MOA proteins (score &gt;0.01), and their associated pathways are shown in Table <xref rid="Tab5" ref-type="table">5</xref>. There were 125 significant comorbidities (<italic>q</italic> value &lt;0.05) predicted and 33 significant pathways (<italic>q</italic> value &lt;0.05) associated with these seven proteins. The top comorbidity associated with OC was angiosarcoma, a rare cancer of the inner blood and lymph vessels and in very rare cases, it occurs in the ovaries<sup><xref ref-type="bibr" rid="CR53">53</xref></sup>. Patients with epithelial ovarian cancers show an increased risk of skin cancer<sup><xref ref-type="bibr" rid="CR54">54</xref></sup>. OC is also considered to have genetic risk factors<sup><xref ref-type="bibr" rid="CR55">55</xref></sup>. Myxoid leiomyosarcoma is a very rare tumor with similarity to ovarian cancer<sup><xref ref-type="bibr" rid="CR56">56</xref></sup>, and leiomyosarcoma was reported in the ovaries<sup><xref ref-type="bibr" rid="CR57">57</xref></sup>. A study found a relationship between hemoglobin levels and interleukin-6 levels in individuals with untreated epithelial ovarian cancer, indicating an inflammatory role in cancer-associated anemia<sup><xref ref-type="bibr" rid="CR58">58</xref></sup>. Medulloblastoma can arise from ovarian tumors in pregnancy<sup><xref ref-type="bibr" rid="CR59">59</xref></sup>. Uveal cancer is associated with breast cancer and OC<sup><xref ref-type="bibr" rid="CR60">60</xref></sup>. OC is part of urinary system neoplasm. In total, 15 (75%) of top 20 comorbidities have literature evidence.<table-wrap id="Tab5"><label>Table 5</label><caption><p>Top 20 comorbidities, seven comorbidity enriched MOA proteins (with respect to input), and top 20 pathways associated with the prediction OC GWAS-driven results using the gene set from ref. <sup><xref ref-type="bibr" rid="CR52">52</xref></sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="3">Comorbidities</th><th colspan="2">MOA proteins</th><th colspan="2">Pathways</th></tr><tr><th>Disease</th><th>J-score</th><th><italic>q</italic> value</th><th>Gene name</th><th>Score</th><th>Pathway</th><th><italic>q</italic> value</th></tr></thead><tbody><tr><td>angiosarcoma</td><td>0.0047</td><td>0.012</td><td>RAD51C</td><td>0.41</td><td>DNA repair</td><td>3.80 × 10<sup>−8</sup></td></tr><tr><td>skin cancer</td><td>0.0036</td><td>0.012</td><td>RAD51D</td><td>0.39</td><td>Diseases of DNA repair</td><td>6.48 × 10<sup>−8</sup></td></tr><tr><td>skin benign neoplasm</td><td>0.0036</td><td>0.012</td><td>MSH6</td><td>0.39</td><td>Mismatch repair</td><td>1.23 × 10<sup>−7</sup></td></tr><tr><td>ovarian carcinoma</td><td>0.0036</td><td>0.024</td><td>MSH2</td><td>0.25</td><td>Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha)</td><td>1.23 × 10<sup>−7</sup></td></tr><tr><td>biliary tract disease</td><td>0.0035</td><td>0.028</td><td>MLH1</td><td>0.12</td><td>Resolution of D-loop structures through synthesis-dependent strand annealing (SDSA)</td><td>5.59 × 10<sup>−7</sup></td></tr><tr><td>genetic disease</td><td>0.0033</td><td>0.012</td><td>BRIP1</td><td>0.065</td><td>Transcriptional regulation by TP53</td><td>8.02 × 10<sup>−7</sup></td></tr><tr><td>myxoid leiomyosarcoma</td><td>0.0032</td><td>0.017</td><td>STK11</td><td>0.050</td><td>Resolution of D-loop structures</td><td>8.02 × 10<sup>−7</sup></td></tr><tr><td>epithelioid leiomyosarcoma</td><td>0.0032</td><td>0.017</td><td/><td/><td>Resolution of D-loop structures through holliday junction intermediates</td><td>8.02 × 10<sup>−7</sup></td></tr><tr><td>leiomyosarcoma</td><td>0.0032</td><td>0.017</td><td/><td/><td>Presynaptic phase of homologous DNA pairing and strand exchange</td><td>1.09 × 10<sup>−6</sup></td></tr><tr><td>mesenchymoma</td><td>0.0031</td><td>0.019</td><td/><td/><td>Homologous DNA pairing and strand exchange</td><td>1.23 × 10<sup>−6</sup></td></tr><tr><td>hematopoietic system disease</td><td>0.0031</td><td>0.019</td><td/><td/><td>TP53 regulates the transcription of DNA repair genes</td><td>4.22 × 10<sup>−6</sup></td></tr><tr><td>lymphatic system disease</td><td>0.0031</td><td>0.039</td><td/><td/><td>HDR through homologous recombination (HRR)</td><td>4.24 × 10<sup>−6</sup></td></tr><tr><td>childhood medulloblastoma</td><td>0.0031</td><td>0.012</td><td/><td/><td>Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta)</td><td>1.61 × 10<sup>−5</sup></td></tr><tr><td>adult medulloblastoma</td><td>0.0031</td><td>0.012</td><td/><td/><td>HDR through homologous recombination (HRR) or single-strand annealing (SSA)</td><td>2.79 × 10<sup>−5</sup></td></tr><tr><td>medullomyoblastoma</td><td>0.0031</td><td>0.012</td><td/><td/><td>Homology directed repair</td><td>2.98 × 10<sup>−5</sup></td></tr><tr><td>chondrosarcoma</td><td>0.0031</td><td>0.019</td><td/><td/><td>DNA double-strand break repair</td><td>4.83 × 10<sup>−5</sup></td></tr><tr><td>pancreas disease</td><td>0.0031</td><td>0.041</td><td/><td/><td>Meiotic recombination</td><td>4.85 × 10<sup>−4</sup></td></tr><tr><td>metachromatic leukodystrophy</td><td>0.0030</td><td>0.021</td><td/><td/><td>Regulation of TP53 activity through phosphorylation</td><td>5.23 × 10<sup>−4</sup></td></tr><tr><td>uveal cancer</td><td>0.0030</td><td>0.021</td><td/><td/><td>Meiosis</td><td>8.11 × 10<sup>−4</sup></td></tr><tr><td>urinary system benign neoplasm</td><td>0.0029</td><td>0.024</td><td/><td/><td>Reproduction</td><td>1.12 × 10<sup>−3</sup></td></tr></tbody></table></table-wrap></p>
      <p id="Par29">The top two comorbidity enriched MOA proteins are RAD51C, RAD51D and belong to 16 of the top 20 pathways. These involve such processes as DNA repair, transcriptional regulation by TP53, DNA double-strand break repair, and reproduction (see Table <xref rid="Tab5" ref-type="table">5</xref>). The top two and the third-ranked MSH6 proteins are shared by all top 100 comorbidities. For example, RAD51C is associated with Fanconi anemia (ranked 63th)<sup><xref ref-type="bibr" rid="CR61">61</xref></sup>; RAD51D is associated with leiomyosarcoma<sup><xref ref-type="bibr" rid="CR62">62</xref></sup>, and MSH6 is a risk gene for pancreatic adenocarcinoma (26th)<sup><xref ref-type="bibr" rid="CR63">63</xref></sup>.</p>
    </sec>
    <sec id="Sec11">
      <title>LeMeDISCO web server</title>
      <p id="Par30">The <bold>LeMeDISCO</bold> web service allows researchers to query our library of 3608 diseases or input a set of pathogenic human genes/proteins and compute their predicted comorbidities, prioritized MOA proteins, and pathways associated. The web service is freely available for academic users at <ext-link ext-link-type="uri" xlink:href="http://sites.gatech.edu/cssb/LeMeDISCO">http://sites.gatech.edu/cssb/LeMeDISCO</ext-link>. The programs and input data for reproducing disease–protein, disease–disease relationships, and all <bold>LeMeDISCO</bold> results as well as benchmark results are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hzhou3ga/lemedisco">https://github.com/hzhou3ga/lemedisco</ext-link>.</p>
    </sec>
  </sec>
  <sec id="Sec12" sec-type="discussion">
    <title>Discussion</title>
    <p id="Par31"><bold>LeMeDISCO</bold> is a systematic approach for studying and analyzing possible features underlying the common proteins driving comorbid diseases. The resulting predicted driver proteins and pathways for each disease or input gene set can allow researchers to generate new diagnostic and treatment options and hypotheses. Interestingly, there were some MOA proteins and pathways present across approximately a third of the diseases, implying common disease drivers. The implications of this observation and its relationship to disease origins will be pursued in future work. We do note that the current comorbid disease analysis strongly suggests that the “one target-one disease-one molecule” approach often used in developing disease therapeutics<sup><xref ref-type="bibr" rid="CR31">31</xref></sup> is likely too simplistic.</p>
    <p id="Par32">To fully understand the complexities of a disease, one must trace the origin of its pathogenesis, which may be due to a genetic or somatic variant that is somehow related to the disease. However, such variants may also be associated with a disease not previously known to be associated with that disease. Such interrelations can be further investigated by identifying high confidence comorbidity predictions from <bold>LeMeDISCO</bold>, regardless of whether or not their comorbidity was previously known in the literature. For example, analysis of the comorbid diseases associated with CAD and OC have not only recapitulated known disease comorbidities but have also provided novel insights. The results for CAD yielded high confidence associations between liver diseases and forms of asthma, which can be further investigated through the comorbidity enriched MOA proteins and pathways. Furthermore, the results for OC revealed more high confidence associations to other forms of cancer such as squamous cell carcinoma and lung cancer.</p>
    <p id="Par33"><bold>LeMeDISCO</bold> not only has applications to the study of the underlying etiology behind a disease but may also be used during the early stages of drug discovery to identify efficacious drugs. Rather than starting with a small molecule or protein target of choice, <bold>LeMeDISCO</bold> allows one to begin at the level of disease biology, often termed phenotypic drug discovery. In future work, we shall demonstrate the utility of <bold>LeMeDISCO</bold> in identifying efficacious drugs to treat a given disease. Overall, the results of the current analysis and preliminary applications to drug discovery suggest that <bold>LeMeDISCO</bold> provides a set of tools for elucidating disease etiology and interrelationships and that a more systems-wide, comprehensive approach to both personalized medicine and drug discovery is required.</p>
    <p id="Par34">We note that some of the predicted MOA proteins are present in around 1/3 of diseases. The top five (AR, NR4A3, PGR, NR3C2, and NR3C1) proteins all belong to the nuclear receptor family and regulate other genes. All have DNA binding sites, especially two zinc finger domains<sup><xref ref-type="bibr" rid="CR64">64</xref></sup>. The regulatory functions and ubiquity of well-studied zinc fingers in these proteins may explain their frequent presentation as disease MOA proteins<sup><xref ref-type="bibr" rid="CR65">65</xref></sup>. Even though in our predicted drug targets of the probe drugs, these proteins are not the most frequent ones (e.g., AR is ranked 1135th of 16,762), their disease associations were enriched by MEDICASCY predicted disease–drug relationships.</p>
    <p id="Par35">With the above possible applications, there is also the limitation of the current approach of using FDA-approved DrugBank drugs as probe drugs to tease out the MOA proteins of diseases, i.e., some possible MOA proteins of a given disease might not be the targets of the probe drugs and others might be incorrectly assigned. This will be addressed in future work that includes more diverse small molecule drug libraries and improved virtual ligand screening algorithms to map the drugs to their respective protein targets<sup><xref ref-type="bibr" rid="CR66">66</xref></sup>. As the probe drug target space is expanded, additional MOA proteins will be discovered. Concomitantly, as the virtual ligand screening algorithms that assign small molecules to their predicted protein targets improve, false positives will be eliminated, and additional true positive proteins might be added. These will result in more accurate MOA protein predictions.</p>
    <p id="Par36">Similar to previous work<sup><xref ref-type="bibr" rid="CR1">1</xref>,<xref ref-type="bibr" rid="CR6">6</xref>–<xref ref-type="bibr" rid="CR8">8</xref></sup>, our predicted disease–disease relationships were benchmarked using large-scale clinical data and have only small-scale validation by literature searches. One single relationship requires at least one published work to validate. Large-scale automatic text mining is a feasible way to scale up the validation and build a more confident subset of our predictions<sup><xref ref-type="bibr" rid="CR67">67</xref></sup>. This is the subject of ongoing studies.</p>
  </sec>
  <sec id="Sec13">
    <title>Methods</title>
    <sec id="Sec14">
      <title>Overview of LeMeDISCO</title>
      <p id="Par37">A flowchart of <bold>LeMeDISCO</bold> is shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. <bold>LeMeDISCO</bold> employs <bold>MEDICASCY</bold><sup><xref ref-type="bibr" rid="CR12">12</xref></sup> to predict possible disease MOA proteins. Here, <bold>MEDICASCY</bold> is applied in prediction mode (i.e., any training drugs having a Tanimoto-Coefficient = 1 to a given input drug is excluded from training) to avoid a strong bias toward drugs in the training set on a set of 2095 FDA-approved drugs<sup><xref ref-type="bibr" rid="CR68">68</xref></sup>. For each of the 3608 indications, we rank the 2095 probe drugs according to their <italic>Z</italic>-scores, <italic>Z</italic><sub><italic>d</italic></sub>, defined using the raw score computed by <bold>MEDICASCY</bold> from:<disp-formula id="Equ1"><label>1</label><alternatives><tex-math id="M9">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${Z}_{d}=\left(\frac{{{{{{{\mathrm{raw}}}}}}}\,{{{{{{\mathrm{score}}}}}}}{{\mbox{--}}}{{{{{{\mathrm{average}}}}}}}\,{{{{{{\mathrm{raw}}}}}}\,{{{{{\mathrm{score}}}}}}}\,{{{{{{\mathrm{of}}}}}}}\,2095\,{{{{{{\mathrm{drugs}}}}}}}}{{{{{{{\mathrm{standard}}}}}}}\,{{{{{{\mathrm{deviation}}}}}}}\,{{{{{{\mathrm{of}}}}}}}\,2095\,{{{{{{\mathrm{raw}}}}}}}\,{{{{{{\mathrm{scores}}}}}}}}\right)$$\end{document}</tex-math><mml:math id="M10"><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">raw</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">score</mml:mi><mml:mstyle><mml:mtext>–</mml:mtext></mml:mstyle><mml:mi mathvariant="normal">average</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">raw</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">score</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mn>2095</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">drugs</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="normal">standard</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">deviation</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">of</mml:mi><mml:mspace width="0.25em"/><mml:mn>2095</mml:mn><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">raw</mml:mi><mml:mspace width="0.25em"/><mml:mi mathvariant="normal">scores</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ1.gif" position="anchor"/></alternatives></disp-formula><fig id="Fig2"><label>Fig. 2</label><caption><title>Schematic representation of <bold>LeMeDISCO</bold>.</title><p><bold>a</bold> The method for determining the MOA proteins associated with a disease indication via <bold>MEDICASCY</bold>, and <bold>b</bold> The method for determining the comorbidities associated with a given disease and its molecular mechanisms via LeMeDISCO.</p></caption><graphic xlink:href="42003_2022_3816_Fig2_HTML" id="d32e4247"/></fig></p>
      <p id="Par38">To predict a drug as having the given indication, we applied a <italic>Z</italic><sub><italic>d</italic></sub> cutoff of 1.65, that approximately corresponds to a <italic>p</italic> value of 0.05 for the upper-tailed null hypotheses of random variable <italic>Z</italic><sub><italic>d</italic></sub>. Thus, for each indication D, the 2095 probe drugs are separated into two groups: <italic>N</italic><sub>1</sub> are predicted to have indication D (<italic>Z</italic><sub><italic>d</italic></sub> ≥ 1.65) and <italic>N</italic><sub>2</sub> (=2095 − <italic>N</italic><sub>1</sub>) are not predicted to have indication <italic>D</italic> (<italic>Z</italic><sub><italic>d</italic></sub> &lt; 1.65). This is a very loose prediction of a drug’s indication with the advantage that it always predicts some drugs having the indication with its expected statistical confidence. Then, for a given indication D and each protein target, T, in the human proteome of our modeled 32,584 proteins, there are a subset of the drugs (or perhaps none) predicted by <bold>FINDSITE</bold><sup><bold>comb2.0</bold></sup>
<sup><xref ref-type="bibr" rid="CR69">69</xref></sup> to bind T. The relative risk RR(D, T) of the given target T with respect to indication D as:<disp-formula id="Equ2"><label>2a</label><alternatives><tex-math id="M11">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{\rm{RR}}}}}}({{{{{\rm{D}}}}}},{{{{{\rm{T}}}}}})=\frac{{N}_{1}^{T}/{N}_{1}}{{N}_{2}^{T}/{N}_{2}}$$\end{document}</tex-math><mml:math id="M12"><mml:mi mathvariant="normal">RR</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">D</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="normal">T</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ2.gif" position="anchor"/></alternatives></disp-formula>where <inline-formula id="IEq5"><alternatives><tex-math id="M13">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{1}^{T}$$\end{document}</tex-math><mml:math id="M14"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq5.gif"/></alternatives></inline-formula> and <inline-formula id="IEq6"><alternatives><tex-math id="M15">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{2}^{T}$$\end{document}</tex-math><mml:math id="M16"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq6.gif"/></alternatives></inline-formula> are the numbers of drugs binding to T with and without indication D, respectively. The numerator is the estimation of the probability of drugs having the predicted indication D (<italic>Z</italic><sub><italic>d</italic></sub> ≥ 1.65) that bind to protein T (F1 = <inline-formula id="IEq7"><alternatives><tex-math id="M17">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{1}^{T}/{N}_{1}$$\end{document}</tex-math><mml:math id="M18"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq7.gif"/></alternatives></inline-formula>). The denominator is the probability of finding drugs that do not have the predicted indication D but which bind to protein T (F2 = <inline-formula id="IEq8"><alternatives><tex-math id="M19">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{2}^{T}/{N}_{2}$$\end{document}</tex-math><mml:math id="M20"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq8.gif"/></alternatives></inline-formula>). This latter probability serves as the background probability that an arbitrary drug will bind to T. When no drug is predicted to bind to protein T, RR(D, T) is set to zero. RR(D, T) = F1/F2 &gt;1 means that a drug having indication D is more likely to bind to T than arbitrary drugs not having the predicted indication D will bind to T.</p>
      <p id="Par39">We then compute the statistical significance of RR(D, T) by calculating a <italic>p</italic> value using Fisher’s exact test<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR71">71</xref></sup> on the following contingency table:<disp-formula id="Equ3"><label>2b</label><alternatives><tex-math id="M21">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left(\begin{array}{cc}{N}_{1}^{T} &amp; {N}_{1}-{N}_{1}^{T}\\ {N}_{2}^{T} &amp; {N}_{2}-{N}_{2}^{T}\end{array}\right)$$\end{document}</tex-math><mml:math id="M22"><mml:mfenced close=")" open="("><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mtd><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mtd><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msubsup><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:msubsup></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ3.gif" position="anchor"/></alternatives></disp-formula></p>
      <p id="Par40">We define a protein target T as predicted to be a possible MOA target for indication D if its <italic>p</italic> value &lt;0.05 because it is more likely to be targeted by efficacious drugs than arbitrary drugs. Thus, for each of the 3608 indications, there is a list of predicted possible MOA proteins.</p>
      <p id="Par41">To reduce false positive MOAs, we utilized the human protein atlas database (<ext-link ext-link-type="uri" xlink:href="https://www.proteinatlas.org/about/download">https://www.proteinatlas.org/about/download</ext-link>, <italic>normal_tissue.tsv</italic>) of expression profiles for proteins in normal human tissues based on immunohistochemistry using tissue micro arrays<sup><xref ref-type="bibr" rid="CR72">72</xref></sup> to filter those proteins that are “not detected” and not “uncertain” in all tested tissues related to an indication. To determine the tissues related to an indication, tissues are mapped to their ICD-10 main codes and indications having the same main codes are related to the tissue.</p>
      <p id="Par42">Using the input of two sets of putative MOA proteins having a <italic>p</italic> value of &lt;0.05 calculated by Fisher’s exact test<sup><xref ref-type="bibr" rid="CR70">70</xref></sup>, we calculate their Jaccard index<sup><xref ref-type="bibr" rid="CR17">17</xref></sup> J(D<sub>1</sub>,D<sub>2</sub>) (J-score) defined in Eq. <xref rid="Equ4" ref-type="">3</xref>a as<disp-formula id="Equ4"><label>3a</label><alternatives><tex-math id="M23">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{{{{\rm{J}}}}}}{\mbox{-}}{{{{{\rm{score}}}}}}={N}_{s}/({{{{{\rm{N}}}}}}{{{{{\rm{D}}}}}}1+{{{{{\rm{N}}}}}}{{{{{\rm{D}}}}}}2-{N}_{s})$$\end{document}</tex-math><mml:math id="M24"><mml:mi mathvariant="normal">J</mml:mi><mml:mstyle><mml:mtext>-</mml:mtext></mml:mstyle><mml:mi mathvariant="normal">score</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mi mathvariant="normal">D</mml:mi><mml:mn>2</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ4.gif" position="anchor"/></alternatives></disp-formula>We then calculate the <italic>p</italic> value for significance by Fisher’s exact test for the contingency table<sup><xref ref-type="bibr" rid="CR70">70</xref></sup> that gives the probability of having overlap ≥<italic>N</italic><sub><italic>s</italic></sub> by randomly selecting <inline-formula id="IEq9"><alternatives><tex-math id="M25">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{D2}$$\end{document}</tex-math><mml:math id="M26"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq9.gif"/></alternatives></inline-formula> out of <inline-formula id="IEq10"><alternatives><tex-math id="M27">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{t}$$\end{document}</tex-math><mml:math id="M28"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq10.gif"/></alternatives></inline-formula> proteins<sup><xref ref-type="bibr" rid="CR70">70</xref>,<xref ref-type="bibr" rid="CR73">73</xref></sup>:<disp-formula id="Equ5"><label>3b</label><alternatives><tex-math id="M29">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\left(\begin{array}{cc}{N}_{s} &amp; {N}_{D2}-{N}_{s}\\ {N}_{D1} &amp; {N}_{t}-{N}_{D1}\end{array}\right)$$\end{document}</tex-math><mml:math id="M30"><mml:mfenced close=")" open="("><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mtd><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd columnalign="center"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ5.gif" position="anchor"/></alternatives></disp-formula><inline-formula id="IEq11"><alternatives><tex-math id="M31">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{D1}$$\end{document}</tex-math><mml:math id="M32"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq11.gif"/></alternatives></inline-formula>, <inline-formula id="IEq12"><alternatives><tex-math id="M33">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{D2}$$\end{document}</tex-math><mml:math id="M34"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq12.gif"/></alternatives></inline-formula> are the numbers of MOA proteins/genes of disease D<sub>1</sub> and D<sub>2</sub>; <italic>N</italic><sub><italic>s</italic></sub> is the number of overlapped MOA proteins between D<sub>1</sub>, D<sub>2</sub>, and <inline-formula id="IEq14"><alternatives><tex-math id="M35">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{t}$$\end{document}</tex-math><mml:math id="M36"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq14.gif"/></alternatives></inline-formula> is the total number of human proteins. The Jaccard index J-score is a statistical measure of the similarity between MOA proteins of D<sub>1</sub> and D<sub>2,</sub> and its value ranges between 0 and 1. Since the null hypothesis of <inline-formula id="IEq15"><alternatives><tex-math id="M37">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{s}$$\end{document}</tex-math><mml:math id="M38"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq15.gif"/></alternatives></inline-formula> corresponds to a hypergeometric distribution, the <italic>p</italic> value of observing the number of overlapped MOA proteins between D<sub>1</sub>, D<sub>2</sub>
<inline-formula id="IEq16"><alternatives><tex-math id="M39">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$$\ge$$\end{document}</tex-math><mml:math id="M40"><mml:mo>≥</mml:mo></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq16.gif"/></alternatives></inline-formula>
<inline-formula id="IEq17"><alternatives><tex-math id="M41">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${N}_{s}$$\end{document}</tex-math><mml:math id="M42"><mml:msub><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mi>s</mml:mi></mml:mrow></mml:msub></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq17.gif"/></alternatives></inline-formula> can be calculated using Fisher’s exact test on the table in Eq. <xref rid="Equ4" ref-type="">3</xref>b<sup><xref ref-type="bibr" rid="CR71">71</xref></sup>. We will use the J-score for predicting comorbidity and compare it with the observed comorbidity. We note that the J-score is determined by the number of overlapped MOAs, which means that the comorbidity defined by the J-score are not limited by diseases occurring in one individual but rather considers the effect of the malfunctioning proteins in the human population. This is especially true for sex-specific diseases such as ovarian cancer and prostate cancer that may have overlapping MOA proteins; this may result in significant comorbidity between them. In other words, the two diseases may share common driver proteins, although ovarian and prostate cancer could occur unless the individual has both an ovary and a prostate, which is highly unlikely. Similarly, it can predict the comorbidity of rare and common diseases; again, whether this would occur would depend on the presence in a given person of the appropriate set of malfunctioning genes. Therefore, though many of the LeMeDISCO comorbidity predictions are seen in one individual, others may not be. Thus, LeMeDISCO comorbidity predictions are a population-based approach.</p>
      <p id="Par43">To better control the false discovery rate (FDR) due to background noise from statistic errors, we performed the multiple testing correction to the <italic>p</italic> values for disease–protein and disease–disease associations calculated by Fisher’s exact test by computing the <italic>q</italic> value using the method described in ref. <sup><xref ref-type="bibr" rid="CR74">74</xref></sup>.</p>
      <p id="Par44">In large-scale disease–disease comorbidity calculations, we use the MOAs predicted by <bold>MEDICASCY</bold><sup><xref ref-type="bibr" rid="CR12">12</xref></sup>. In addition, MOA targets between disease pairs can also be derived from experimental data; examples include differential gene expression (GE), Mendelian or somatic mutation profiles comparing disease vs. control normal samples, better vs. worse prognosis samples, or drug-treated vs. control untreated samples<sup><xref ref-type="bibr" rid="CR75">75</xref></sup>.</p>
    </sec>
    <sec id="Sec15">
      <title>Benchmarking of LeMeDISCO</title>
      <p id="Par45">We validated <bold>LeMeDISCO</bold>’s J-score by correlating it with the observed comorbidity as quantified by (a) the logarithm of relative risk log(RR) score and (b) the φ<bold>-</bold>score (Pearson’s correlation for binary variables)<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>. The relative risk (RR) is the probability that two diseases co-occur in a single individual relative to random. Since RR scales exponentially with respect to the strength of two interacting diseases, we use log(RR) for correlation analysis. The log(RR) and φ<bold>-</bold>score are computed from US Medicare insurance claim data using<sup><xref ref-type="bibr" rid="CR1">1</xref></sup>:<disp-formula id="Equ6"><label>4a</label><alternatives><tex-math id="M43">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\log }}({{{{{\rm{RR}}}}}})\,=\,{{\log }}\left(\frac{{n}_{{AB}}/{n}_{{tot}}} {({n}_{A}/{n}_{{tot}}){({n}_{B}/{n}_{{tot}})}}\right)$$\end{document}</tex-math><mml:math id="M44"><mml:mi>log</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="normal">RR</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:mi>log</mml:mi><mml:mfenced close=")" open="("><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ6.gif" position="anchor"/></alternatives></disp-formula><disp-formula id="Equ7"><label>4b</label><alternatives><tex-math id="M45">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${{\varphi }}{\mbox{-}}{{{{{\rm{score}}}}}}=({n}_{{AB}}* {n}_{{tot}}-{n}_{A}* {n}_{B})/\sqrt{{n}_{A}* {n}_{B}* \left({n}_{{tot}}-{n}_{A}\right)* \left({n}_{{tot}}-{n}_{B}\right)}$$\end{document}</tex-math><mml:math id="M46"><mml:mi>φ</mml:mi><mml:mstyle><mml:mtext>-</mml:mtext></mml:mstyle><mml:mi mathvariant="normal">score</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:msqrt><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub><mml:mo>*</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>A</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced><mml:mo>*</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>n</mml:mi></mml:mrow><mml:mrow><mml:mi>B</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfenced></mml:mrow></mml:msqrt></mml:math><graphic xlink:href="42003_2022_3816_Article_Equ7.gif" position="anchor"/></alternatives></disp-formula>where <italic>n</italic><sub><italic>tot</italic></sub> = total number of patients; <italic>n</italic><sub><italic>A</italic></sub>, <italic>n</italic><sub><italic>B</italic></sub> = number of patients diagnosed with diseases A and B, and <italic>n</italic><sub><italic>AB</italic></sub> = number of patients diagnosed with both diseases A and B.</p>
    </sec>
    <sec id="Sec16">
      <title>Permutation tests</title>
      <p id="Par46">Two permutation tests were performed: (a) Permute drug–protein relationships: Randomly permute the predicted drug–protein relations (i.e., randomly replace a drug’s protein targets with another drug’s protein targets predicted by <bold>FINDSITE</bold><sup><bold>comb2.0</bold></sup>). This acts to transfer the protein targets of a drug (possibly incorrectly) to another drug. This test evaluates the performance of <bold>LeMeDISCO</bold> if we have the correct drug–disease relations (predicted by <bold>MEDICASCY</bold>) but the incorrect drug–protein relations. To ensure the correct drug–disease relations after permuting the drug–protein relations, <bold>MEDICASCY</bold> was applied to the permuted drug–protein relations since <bold>MEDICASCY</bold> depends on the drug’s protein targets; (b) Permute drug–disease relationships: Randomly permute the predicted drug–disease relations (by randomly replacing a drug’s predicted indications with another drug’s indications). This test evaluates how <bold>LeMeDISCO</bold> will perform if the drug–protein relations are correct (predicted by <bold>FINDSITE</bold><sup><bold>comb2.0</bold></sup>), but the drug–disease relations are randomly permuted. In both cases, disease MOAs are derived using the permuted relationships and 100 runs for each test with different random seeds were performed. A <italic>p</italic> value is calculated from <italic>z</italic>-score = (LeMeDISCO value-average)/standard deviation to characterize the significance of the difference between <bold>LeMeDISCO</bold> and the permutation tests.</p>
    </sec>
    <sec id="Sec17">
      <title>Identification of key MOA proteins and associated pathways for disease comorbidity</title>
      <p id="Par47">After determining the significant comorbidities for each disease, the <italic>p</italic> value weighted frequency of shared MOA proteins across the top 100 predicted comorbidities are calculated. We define a <italic>p</italic> value weighted frequency of an input MOA as follows (i.e., CoMOAenrich score): If MOA protein T is shared by a comorbid indication D and the <italic>p</italic> value of T associated with D is <italic>P</italic>, then the weight defined by the min(1.0,−αlog<italic>P</italic>) is counted as T’s frequency. In practice, we used 10 cancer cell line data<sup><xref ref-type="bibr" rid="CR76">76</xref></sup> to optimize the coefficient α to 0.025. We further computed a <italic>p</italic> value via <inline-formula id="IEq18"><alternatives><tex-math id="M47">\documentclass[12pt]{minimal}
				\usepackage{amsmath}
				\usepackage{wasysym} 
				\usepackage{amsfonts} 
				\usepackage{amssymb} 
				\usepackage{amsbsy}
				\usepackage{mathrsfs}
				\usepackage{upgreek}
				\setlength{\oddsidemargin}{-69pt}
				\begin{document}$${e}^{-\frac{{{{{{{\mathrm{COMOAenrich}}}}}}\; {{{{{\mathrm{score}}}}}}}}{\alpha }}$$\end{document}</tex-math><mml:math id="M48"><mml:msup><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">COMOAenrich</mml:mi><mml:mspace width="0.16em"/><mml:mi mathvariant="normal">score</mml:mi></mml:mrow><mml:mrow><mml:mi>α</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:msup></mml:math><inline-graphic xlink:href="42003_2022_3816_Article_IEq18.gif"/></alternatives></inline-formula> where α = 0.025, as previously mentioned. These MOA proteins expand the number of possible molecular players driving disease pathogenesis. An empirically derived CoMOAenrich score (normalized by the number of comorbid indications that is 100) threshold of 0.01 was used, which is equivalent to 1% of the comorbid indications having the MOA proteins with a significant <italic>p</italic> value (&lt;4.2 × 10<sup>−18</sup>). Then, up to the top 100 comorbidity enriched MOA proteins for each disease were used in global pathway analysis via Reactome<sup><xref ref-type="bibr" rid="CR13">13</xref></sup>. The pathways with a <italic>p</italic> value &lt;0.05 were extracted. The frequency of pathways across diseases was assessed to identify common pathways of disease.</p>
    </sec>
    <sec id="Sec18">
      <title>LeMeDISCO usage</title>
      <p id="Par48">As shown in Fig. <xref rid="Fig2" ref-type="fig">2</xref>, <bold>LeMeDISCO</bold> can be used in two different ways: (1) <bold>MEDICASCY</bold>-driven <bold>LeMeDISCO</bold>: The comorbidities for any of the 3608 diseases from the <bold>MEDICASCY</bold>-provided MOA proteins are predicted (Fig. <xref rid="Fig2" ref-type="fig">2a</xref>). (2) Pathogenic gene set driven <bold>LeMeDISCO</bold>: Input your own pathogenic gene set derived from differential gene expression, GWAS, exome analysis, or other experimental/clinical techniques (shown in Fig. <xref rid="Fig2" ref-type="fig">2b</xref>). The <bold>LeMeDISCO</bold> web service allows users to query the <bold>LeMeDISCO</bold> database as well as input their own set of pathogenic genes to assess the associated comorbidities, MOA proteins, and pathways.</p>
    </sec>
    <sec id="Sec19">
      <title>Reporting summary</title>
      <p id="Par49">Further information on research design is available in the <xref rid="MOESM4" ref-type="media">Nature Research Reporting Summary</xref> linked to this article.</p>
    </sec>
  </sec>
  <sec sec-type="supplementary-material">
    <title>Supplementary information</title>
    <sec id="Sec20">
      <p>
        <supplementary-material content-type="local-data" id="MOESM1">
          <media xlink:href="42003_2022_3816_MOESM1_ESM.pdf">
            <caption>
              <p>Supplementary Information</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM2">
          <media xlink:href="42003_2022_3816_MOESM2_ESM.pdf">
            <caption>
              <p>Description of Additional Supplementary Files</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM3">
          <media xlink:href="42003_2022_3816_MOESM3_ESM.xlsx">
            <caption>
              <p>Supplementary Data 1</p>
            </caption>
          </media>
        </supplementary-material>
        <supplementary-material content-type="local-data" id="MOESM4">
          <media xlink:href="42003_2022_3816_MOESM4_ESM.pdf">
            <caption>
              <p>Reporting Summary</p>
            </caption>
          </media>
        </supplementary-material>
      </p>
    </sec>
  </sec>
</body>
<back>
  <fn-group>
    <fn>
      <p><bold>Publisher’s note</bold> Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
    </fn>
    <fn>
      <p>These authors contributed equally: Courtney Astore, Hongyi Zhou.</p>
    </fn>
  </fn-group>
  <sec>
    <title>Supplementary information</title>
    <p>The online version contains supplementary material available at 10.1038/s42003-022-03816-9.</p>
  </sec>
  <ack>
    <title>Acknowledgements</title>
    <p>This project was funded by R35GM118039 of the Division of General Medical Sciences of the NIH.</p>
  </ack>
  <notes notes-type="author-contribution">
    <title>Author contributions</title>
    <p>C.A., H.Z., and J.S. conceived of the method; C.A. and H.Z. implemented the method; H.Z., C.A., and J.S. analyzed the data and wrote the paper. C.A., B.I., and J.F. created and implemented the webpage and web service.</p>
  </notes>
  <notes notes-type="peer-review">
    <title>Peer review</title>
    <sec id="FPar1">
      <title>Peer review information</title>
      <p id="Par50"><italic>Communications Biology</italic> thanks the anonymous reviewers for their contribution to the peer review of this work. Primary Handling Editors: Eirini Marouli and Gene Chong.</p>
    </sec>
  </notes>
  <notes notes-type="data-availability">
    <title>Data availability</title>
    <p>The input data for reproducing disease–protein, disease–disease relationships, and all <bold>LeMeDISCO</bold> results as well as benchmark results are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hzhou3ga/lemedisco">https://github.com/hzhou3ga/lemedisco</ext-link>. The web service is freely available for academic users at <ext-link ext-link-type="uri" xlink:href="http://sites.gatech.edu/cssb/LeMeDISCO">http://sites.gatech.edu/cssb/LeMeDISCO</ext-link>. The underline data for Fig. <xref rid="Fig1" ref-type="fig">1</xref> is in file supplementary data <xref rid="MOESM3" ref-type="media">1</xref>.</p>
  </notes>
  <notes notes-type="data-availability">
    <title>Code availability</title>
    <p>The programs for reproducing disease–protein and disease–disease relationships are available at <ext-link ext-link-type="uri" xlink:href="https://github.com/hzhou3ga/lemedisco">https://github.com/hzhou3ga/lemedisco</ext-link>.</p>
  </notes>
  <notes id="FPar2" notes-type="COI-statement">
    <title>Competing interests</title>
    <p id="Par51">The authors declare no competing interests.</p>
  </notes>
  <ref-list id="Bib1">
    <title>References</title>
    <ref id="CR1">
      <label>1.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hidalgo</surname>
            <given-names>CA</given-names>
          </name>
          <name>
            <surname>Blumm</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Barabasi</surname>
            <given-names>AL</given-names>
          </name>
          <name>
            <surname>Christakis</surname>
            <given-names>NA</given-names>
          </name>
        </person-group>
        <article-title>A dynamic network approach for the study of human phenotypes</article-title>
        <source>PLoS Comput. Biol.</source>
        <year>2009</year>
        <volume>5</volume>
        <fpage>e1000353</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pcbi.1000353</pub-id>
        <?supplied-pmid 19360091?>
        <pub-id pub-id-type="pmid">19360091</pub-id>
      </element-citation>
    </ref>
    <ref id="CR2">
      <label>2.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Somers</surname>
            <given-names>EC</given-names>
          </name>
          <name>
            <surname>Thomas</surname>
            <given-names>SL</given-names>
          </name>
          <name>
            <surname>Smeeth</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>AJ</given-names>
          </name>
        </person-group>
        <article-title>Are individuals with an autoimmune disease at higher risk of a second autoimmune disorder</article-title>
        <source>Am. J. Epidemiol.</source>
        <year>2009</year>
        <volume>169</volume>
        <fpage>749</fpage>
        <lpage>755</lpage>
        <pub-id pub-id-type="doi">10.1093/aje/kwn408</pub-id>
        <?supplied-pmid 19224981?>
        <pub-id pub-id-type="pmid">19224981</pub-id>
      </element-citation>
    </ref>
    <ref id="CR3">
      <label>3.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cramer</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Waldorp</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>van der Maas</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Borsboom</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>Comorbidity: a network perspective</article-title>
        <source>Behav. Brain Sci.</source>
        <year>2010</year>
        <volume>33</volume>
        <fpage>137</fpage>
        <lpage>150</lpage>
        <pub-id pub-id-type="doi">10.1017/S0140525X09991567</pub-id>
        <?supplied-pmid 20584369?>
        <pub-id pub-id-type="pmid">20584369</pub-id>
      </element-citation>
    </ref>
    <ref id="CR4">
      <label>4.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Melamed</surname>
            <given-names>RD</given-names>
          </name>
          <name>
            <surname>Emmett</surname>
            <given-names>KJ</given-names>
          </name>
          <name>
            <surname>Madubata</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Genetic similarity between cancers and comorbid Mendelian diseases identifies candidate driver genes</article-title>
        <source>Nat. Commun.</source>
        <year>2015</year>
        <volume>6</volume>
        <fpage>7033</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms8033</pub-id>
        <?supplied-pmid 25926297?>
        <pub-id pub-id-type="pmid">25926297</pub-id>
      </element-citation>
    </ref>
    <ref id="CR5">
      <label>5.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>D-S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The implications of human metabolic network topology for disease comorbidity</article-title>
        <source>Proc. Natl Acad. Sci. USA</source>
        <year>2008</year>
        <volume>105</volume>
        <fpage>9880</fpage>
        <lpage>9885</lpage>
        <pub-id pub-id-type="doi">10.1073/pnas.0802208105</pub-id>
        <?supplied-pmid 18599447?>
        <pub-id pub-id-type="pmid">18599447</pub-id>
      </element-citation>
    </ref>
    <ref id="CR6">
      <label>6.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>X</given-names>
          </name>
          <name>
            <surname>Menche</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Barabási</surname>
            <given-names>A-L</given-names>
          </name>
          <name>
            <surname>Sharma</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>Human symptoms–disease network</article-title>
        <source>Nat. Commun.</source>
        <year>2014</year>
        <volume>5</volume>
        <fpage>4212</fpage>
        <pub-id pub-id-type="doi">10.1038/ncomms5212</pub-id>
        <?supplied-pmid 24967666?>
        <pub-id pub-id-type="pmid">24967666</pub-id>
      </element-citation>
    </ref>
    <ref id="CR7">
      <label>7.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Menche</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Disease networks. Uncovering disease-disease relationships through the incomplete interactomes</article-title>
        <source>interactome. Science</source>
        <year>2015</year>
        <volume>347</volume>
        <fpage>1257601</fpage>
        <?supplied-pmid 25700523?>
        <pub-id pub-id-type="pmid">25700523</pub-id>
      </element-citation>
    </ref>
    <ref id="CR8">
      <label>8.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ko</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Cho</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Lee</surname>
            <given-names>J-S</given-names>
          </name>
          <name>
            <surname>Kim</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Identification of disease comorbidity through hidden molecular mechanisms</article-title>
        <source>Sci. Rep.</source>
        <year>2016</year>
        <volume>6</volume>
        <fpage>39433</fpage>
        <pub-id pub-id-type="doi">10.1038/srep39433</pub-id>
        <?supplied-pmid 27991583?>
        <pub-id pub-id-type="pmid">27991583</pub-id>
      </element-citation>
    </ref>
    <ref id="CR9">
      <label>9.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Analysis of disease comorbidity patterns in a large-scale China population</article-title>
        <source>BMC Med. Genomics</source>
        <year>2019</year>
        <volume>12</volume>
        <fpage>177</fpage>
        <pub-id pub-id-type="doi">10.1186/s12920-019-0629-x</pub-id>
        <?supplied-pmid 31829182?>
        <pub-id pub-id-type="pmid">31829182</pub-id>
      </element-citation>
    </ref>
    <ref id="CR10">
      <label>10.</label>
      <mixed-citation publication-type="other">Ramos, E. M. et al. Phenotype–Genotype Integrator (PheGenI): synthesizing genome-wide association study (GWAS) data with existing genomic resources. <italic>Eur. J. Hum. Genet</italic>. 22, 144–147 (2014)..</mixed-citation>
    </ref>
    <ref id="CR11">
      <label>11.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Schriml</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Disease ontology: a backbone for disease semantic integration</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2012</year>
        <volume>40</volume>
        <fpage>D940</fpage>
        <lpage>D946</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkr972</pub-id>
        <?supplied-pmid 22080554?>
        <pub-id pub-id-type="pmid">22080554</pub-id>
      </element-citation>
    </ref>
    <ref id="CR12">
      <label>12.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>MEDICASCY: a machine learning approach for predicting small-molecule drug side effects, indications, efficacy, and modes of action</article-title>
        <source>Mol. Pharm.</source>
        <year>2020</year>
        <volume>17</volume>
        <fpage>1558</fpage>
        <lpage>1574</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.molpharmaceut.9b01248</pub-id>
        <?supplied-pmid 32237745?>
        <pub-id pub-id-type="pmid">32237745</pub-id>
      </element-citation>
    </ref>
    <ref id="CR13">
      <label>13.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jassal</surname>
            <given-names>B</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The reactome pathway knowledgebase</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2020</year>
        <volume>48</volume>
        <fpage>D498</fpage>
        <lpage>d503</lpage>
        <?supplied-pmid 31691815?>
        <pub-id pub-id-type="pmid">31691815</pub-id>
      </element-citation>
    </ref>
    <ref id="CR14">
      <label>14.</label>
      <mixed-citation publication-type="other">Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. <italic>Nature</italic>10.1038/s41586-021-03819-2 (2021).</mixed-citation>
    </ref>
    <ref id="CR15">
      <label>15.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Carpenter</surname>
            <given-names>KA</given-names>
          </name>
          <name>
            <surname>Cohen</surname>
            <given-names>DS</given-names>
          </name>
          <name>
            <surname>Jarrell</surname>
            <given-names>JT</given-names>
          </name>
          <name>
            <surname>Huang</surname>
            <given-names>X</given-names>
          </name>
        </person-group>
        <article-title>Deep learning and virtual drug screening</article-title>
        <source>Future Med. Chem.</source>
        <year>2018</year>
        <volume>10</volume>
        <fpage>2557</fpage>
        <lpage>2567</lpage>
        <pub-id pub-id-type="doi">10.4155/fmc-2018-0314</pub-id>
        <?supplied-pmid 30288997?>
        <pub-id pub-id-type="pmid">30288997</pub-id>
      </element-citation>
    </ref>
    <ref id="CR16">
      <label>16.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>ENTPRISE-X: predicting disease-associated frameshift and nonsense mutations</article-title>
        <source>PLoS ONE</source>
        <year>2018</year>
        <volume>13</volume>
        <fpage>e0196849</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0196849</pub-id>
        <?supplied-pmid 29723276?>
        <pub-id pub-id-type="pmid">29723276</pub-id>
      </element-citation>
    </ref>
    <ref id="CR17">
      <label>17.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jaccard</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>THE distribution of the flora in the alpine zone</article-title>
        <source>N. Phytologist</source>
        <year>1912</year>
        <volume>11</volume>
        <fpage>37</fpage>
        <lpage>50</lpage>
        <pub-id pub-id-type="doi">10.1111/j.1469-8137.1912.tb05611.x</pub-id>
      </element-citation>
    </ref>
    <ref id="CR18">
      <label>18.</label>
      <mixed-citation publication-type="other">World Health, O. (World Health Organization, 2004). <ext-link ext-link-type="uri" xlink:href="https://www.cdc.gov/nchs/icd/icd-10-cm.htm">https://www.cdc.gov/nchs/icd/icd-10-cm.htm</ext-link>.</mixed-citation>
    </ref>
    <ref id="CR19">
      <label>19.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rogers</surname>
            <given-names>FB</given-names>
          </name>
        </person-group>
        <article-title>Medical subject headings</article-title>
        <source>Bull. Med. Libr. Assoc.</source>
        <year>1963</year>
        <volume>51</volume>
        <fpage>114</fpage>
        <lpage>116</lpage>
        <?supplied-pmid 13982385?>
        <pub-id pub-id-type="pmid">13982385</pub-id>
      </element-citation>
    </ref>
    <ref id="CR20">
      <label>20.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fuster</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Badimon</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Badimon</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Chesebro</surname>
            <given-names>JH</given-names>
          </name>
        </person-group>
        <article-title>The pathogenesis of coronary artery disease and the acute coronary syndromes</article-title>
        <source>N. Engl. J. Med.</source>
        <year>1992</year>
        <volume>326</volume>
        <fpage>310</fpage>
        <lpage>318</lpage>
        <pub-id pub-id-type="doi">10.1056/NEJM199201303260506</pub-id>
        <?supplied-pmid 1728735?>
        <pub-id pub-id-type="pmid">1728735</pub-id>
      </element-citation>
    </ref>
    <ref id="CR21">
      <label>21.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Gao</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Sheng</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>W</given-names>
          </name>
        </person-group>
        <article-title>Association of asthma with coronary heart disease: a meta analysis of 11 trials</article-title>
        <source>PLoS ONE</source>
        <year>2017</year>
        <volume>12</volume>
        <fpage>e0179335</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0179335</pub-id>
        <?supplied-pmid 28609456?>
        <pub-id pub-id-type="pmid">28609456</pub-id>
      </element-citation>
    </ref>
    <ref id="CR22">
      <label>22.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Aronson</surname>
            <given-names>D</given-names>
          </name>
          <name>
            <surname>Edelman</surname>
            <given-names>ER</given-names>
          </name>
        </person-group>
        <article-title>Coronary artery disease and diabetes mellitus</article-title>
        <source>Cardiol. Clin.</source>
        <year>2014</year>
        <volume>32</volume>
        <fpage>439</fpage>
        <lpage>455</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ccl.2014.04.001</pub-id>
        <?supplied-pmid 25091969?>
        <pub-id pub-id-type="pmid">25091969</pub-id>
      </element-citation>
    </ref>
    <ref id="CR23">
      <label>23.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Falk</surname>
            <given-names>JA</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Cardiac disease in chronic obstructive pulmonary disease</article-title>
        <source>Proc. Am. Thorac. Soc.</source>
        <year>2008</year>
        <volume>5</volume>
        <fpage>543</fpage>
        <lpage>548</lpage>
        <pub-id pub-id-type="doi">10.1513/pats.200708-142ET</pub-id>
        <?supplied-pmid 18453369?>
        <pub-id pub-id-type="pmid">18453369</pub-id>
      </element-citation>
    </ref>
    <ref id="CR24">
      <label>24.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Montemezzo</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Nonalcoholic fatty liver disease and coronary artery disease: big brothers in patients with acute coronary syndrome</article-title>
        <source>Sci. World J.</source>
        <year>2020</year>
        <volume>2020</volume>
        <fpage>8489238</fpage>
        <pub-id pub-id-type="doi">10.1155/2020/8489238</pub-id>
      </element-citation>
    </ref>
    <ref id="CR25">
      <label>25.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Cai</surname>
            <given-names>Q</given-names>
          </name>
          <name>
            <surname>Mukku</surname>
            <given-names>VK</given-names>
          </name>
          <name>
            <surname>Ahmad</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Coronary artery disease in patients with chronic kidney disease: a clinical update</article-title>
        <source>Curr. Cardiol. Rev.</source>
        <year>2013</year>
        <volume>9</volume>
        <fpage>331</fpage>
        <lpage>339</lpage>
        <pub-id pub-id-type="doi">10.2174/1573403X10666140214122234</pub-id>
        <?supplied-pmid 24527682?>
        <pub-id pub-id-type="pmid">24527682</pub-id>
      </element-citation>
    </ref>
    <ref id="CR26">
      <label>26.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Beyer</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Plank</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Friedrich</surname>
            <given-names>G</given-names>
          </name>
          <name>
            <surname>Wildauer</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Feuchtner</surname>
            <given-names>G</given-names>
          </name>
        </person-group>
        <article-title>Effects of hyperthyroidism on coronary artery disease: a computed tomography angiography study</article-title>
        <source>Can. J. Cardiol.</source>
        <year>2017</year>
        <volume>33</volume>
        <fpage>1327</fpage>
        <lpage>1334</lpage>
        <pub-id pub-id-type="doi">10.1016/j.cjca.2017.07.002</pub-id>
        <?supplied-pmid 28867263?>
        <pub-id pub-id-type="pmid">28867263</pub-id>
      </element-citation>
    </ref>
    <ref id="CR27">
      <label>27.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Crans Yoon</surname>
            <given-names>AM</given-names>
          </name>
          <name>
            <surname>Chiu</surname>
            <given-names>V</given-names>
          </name>
          <name>
            <surname>Rana</surname>
            <given-names>JS</given-names>
          </name>
          <name>
            <surname>Sheikh</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>Association of allergic rhinitis, coronary heart disease, cerebrovascular disease, and all-cause mortality</article-title>
        <source>Ann. Allergy Asthma Immunol.</source>
        <year>2016</year>
        <volume>117</volume>
        <fpage>359</fpage>
        <lpage>364.e351</lpage>
        <pub-id pub-id-type="doi">10.1016/j.anai.2016.08.021</pub-id>
        <?supplied-pmid 27742084?>
        <pub-id pub-id-type="pmid">27742084</pub-id>
      </element-citation>
    </ref>
    <ref id="CR28">
      <label>28.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhu</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Zhang</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Guo</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>M</given-names>
          </name>
        </person-group>
        <article-title>Cardiovascular biology of prostanoids and drug discovery</article-title>
        <source>Arterioscler. Thromb. Vasc. Biol.</source>
        <year>2020</year>
        <volume>40</volume>
        <fpage>1454</fpage>
        <lpage>1463</lpage>
        <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313234</pub-id>
        <?supplied-pmid 32295420?>
        <pub-id pub-id-type="pmid">32295420</pub-id>
      </element-citation>
    </ref>
    <ref id="CR29">
      <label>29.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Gareri</surname>
            <given-names>C</given-names>
          </name>
          <name>
            <surname>Rockman</surname>
            <given-names>HA</given-names>
          </name>
        </person-group>
        <article-title>G-protein-coupled receptors in heart disease</article-title>
        <source>Circ. Res.</source>
        <year>2018</year>
        <volume>123</volume>
        <fpage>716</fpage>
        <lpage>735</lpage>
        <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.118.311403</pub-id>
        <?supplied-pmid 30355236?>
        <pub-id pub-id-type="pmid">30355236</pub-id>
      </element-citation>
    </ref>
    <ref id="CR30">
      <label>30.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van der Harst</surname>
            <given-names>P</given-names>
          </name>
          <name>
            <surname>Verweij</surname>
            <given-names>N</given-names>
          </name>
        </person-group>
        <article-title>Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of Coronary Artery Disease</article-title>
        <source>Circulation Res.</source>
        <year>2018</year>
        <volume>122</volume>
        <fpage>433</fpage>
        <lpage>443</lpage>
        <pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.312086</pub-id>
        <?supplied-pmid 29212778?>
        <pub-id pub-id-type="pmid">29212778</pub-id>
      </element-citation>
    </ref>
    <ref id="CR31">
      <label>31.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zandparsa</surname>
            <given-names>A</given-names>
          </name>
          <name>
            <surname>Habashizadeh</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Moradi Farsani</surname>
            <given-names>E</given-names>
          </name>
          <name>
            <surname>Jabbari</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Rezaei</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Relationship between renal artery stenosis and severity of coronary artery disease in patients with coronary atherosclerotic disease</article-title>
        <source>Int. Cardiovasc. Res. J.</source>
        <year>2012</year>
        <volume>6</volume>
        <fpage>84</fpage>
        <lpage>87</lpage>
        <?supplied-pmid 24757598?>
        <pub-id pub-id-type="pmid">24757598</pub-id>
      </element-citation>
    </ref>
    <ref id="CR32">
      <label>32.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>KJ</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Usefulness of anterior uveitis as an additional tool for diagnosing incomplete Kawasaki disease</article-title>
        <source>Korean J. Pediatr.</source>
        <year>2016</year>
        <volume>59</volume>
        <fpage>174</fpage>
        <lpage>177</lpage>
        <pub-id pub-id-type="doi">10.3345/kjp.2016.59.4.174</pub-id>
        <?supplied-pmid 27186227?>
        <pub-id pub-id-type="pmid">27186227</pub-id>
      </element-citation>
    </ref>
    <ref id="CR33">
      <label>33.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rudnicki</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hypoxia response and VEGF-A expression in human proximal tubular epithelial cells in stable and progressive renal disease</article-title>
        <source>Lab. Invest.</source>
        <year>2009</year>
        <volume>89</volume>
        <fpage>337</fpage>
        <lpage>346</lpage>
        <pub-id pub-id-type="doi">10.1038/labinvest.2008.158</pub-id>
        <?supplied-pmid 19139726?>
        <pub-id pub-id-type="pmid">19139726</pub-id>
      </element-citation>
    </ref>
    <ref id="CR34">
      <label>34.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Paroli</surname>
            <given-names>MP</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Increased vascular endothelial growth factor levels in aqueous humor and serum of patients with quiescent uveitis</article-title>
        <source>Eur. J. Ophthalmol.</source>
        <year>2007</year>
        <volume>17</volume>
        <fpage>938</fpage>
        <lpage>942</lpage>
        <pub-id pub-id-type="doi">10.1177/112067210701700611</pub-id>
        <?supplied-pmid 18050120?>
        <pub-id pub-id-type="pmid">18050120</pub-id>
      </element-citation>
    </ref>
    <ref id="CR35">
      <label>35.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>de-la-Torre</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Uveitis and multiple sclerosis: potential common causal mutations</article-title>
        <source>Mol. Neurobiol.</source>
        <year>2019</year>
        <volume>56</volume>
        <fpage>8008</fpage>
        <lpage>8017</lpage>
        <pub-id pub-id-type="doi">10.1007/s12035-019-1630-2</pub-id>
        <?supplied-pmid 31161422?>
        <pub-id pub-id-type="pmid">31161422</pub-id>
      </element-citation>
    </ref>
    <ref id="CR36">
      <label>36.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Davoudi</surname>
            <given-names>S</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Association of genetic variants in RAB23 and ANXA11 with uveitis in sarcoidosis</article-title>
        <source>Mol. Vis.</source>
        <year>2018</year>
        <volume>24</volume>
        <fpage>59</fpage>
        <lpage>74</lpage>
        <?supplied-pmid 29416296?>
        <pub-id pub-id-type="pmid">29416296</pub-id>
      </element-citation>
    </ref>
    <ref id="CR37">
      <label>37.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Rouillard</surname>
            <given-names>AD</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>The harmonizome: a collection of processed datasets gathered to serve and mine knowledge about genes and proteins</article-title>
        <source>Database</source>
        <year>2016</year>
        <volume>2016</volume>
        <fpage>baw100</fpage>
        <pub-id pub-id-type="doi">10.1093/database/baw100</pub-id>
        <?supplied-pmid 27374120?>
        <pub-id pub-id-type="pmid">27374120</pub-id>
      </element-citation>
    </ref>
    <ref id="CR38">
      <label>38.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Spindler</surname>
            <given-names>SR</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Statin treatment increases lifespan and improves cardiac health in Drosophila by decreasing specific protein prenylation</article-title>
        <source>PLoS ONE</source>
        <year>2012</year>
        <volume>7</volume>
        <fpage>e39581</fpage>
        <pub-id pub-id-type="doi">10.1371/journal.pone.0039581</pub-id>
        <?supplied-pmid 22737247?>
        <pub-id pub-id-type="pmid">22737247</pub-id>
      </element-citation>
    </ref>
    <ref id="CR39">
      <label>39.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Etter</surname>
            <given-names>JL</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hereditary association between testicular cancer and familial ovarian cancer: a familial ovarian cancer registry study</article-title>
        <source>Cancer Epidemiol.</source>
        <year>2018</year>
        <volume>53</volume>
        <fpage>184</fpage>
        <lpage>186</lpage>
        <pub-id pub-id-type="doi">10.1016/j.canep.2018.02.005</pub-id>
        <?supplied-pmid 29499525?>
        <pub-id pub-id-type="pmid">29499525</pub-id>
      </element-citation>
    </ref>
    <ref id="CR40">
      <label>40.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Srivastava</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Shree</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Guleria</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Singh</surname>
            <given-names>UR</given-names>
          </name>
        </person-group>
        <article-title>Pure primary squamous cell carcinoma of ovary - A rare case report</article-title>
        <source>J. Clin. Diagn. Res.</source>
        <year>2017</year>
        <volume>11</volume>
        <fpage>Qd01</fpage>
        <lpage>qd02</lpage>
        <?supplied-pmid 28658855?>
        <pub-id pub-id-type="pmid">28658855</pub-id>
      </element-citation>
    </ref>
    <ref id="CR41">
      <label>41.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Guidozzi</surname>
            <given-names>F</given-names>
          </name>
          <name>
            <surname>Sonnendecker</surname>
            <given-names>EW</given-names>
          </name>
          <name>
            <surname>Wright</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Ovarian cancer with metastatic deposits in the cervix, vagina, or vulva preceding primary cytoreductive surgery</article-title>
        <source>Gynecol. Oncol.</source>
        <year>1993</year>
        <volume>49</volume>
        <fpage>225</fpage>
        <lpage>228</lpage>
        <pub-id pub-id-type="doi">10.1006/gyno.1993.1111</pub-id>
        <?supplied-pmid 8504991?>
        <pub-id pub-id-type="pmid">8504991</pub-id>
      </element-citation>
    </ref>
    <ref id="CR42">
      <label>42.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Bergfeldt</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Nilsson</surname>
            <given-names>B</given-names>
          </name>
          <name>
            <surname>Einhorn</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Hall</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Breast cancer risk in women with a primary ovarian cancer-a case-control study</article-title>
        <source>Eur. J. Cancer</source>
        <year>2001</year>
        <volume>37</volume>
        <fpage>2229</fpage>
        <lpage>2234</lpage>
        <pub-id pub-id-type="doi">10.1016/S0959-8049(01)00282-9</pub-id>
        <?supplied-pmid 11677112?>
        <pub-id pub-id-type="pmid">11677112</pub-id>
      </element-citation>
    </ref>
    <ref id="CR43">
      <label>43.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Losito</surname>
            <given-names>NS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Lung cancer diagnosis on ovary mass: a case report</article-title>
        <source>J. Ovarian Res.</source>
        <year>2013</year>
        <volume>6</volume>
        <fpage>34</fpage>
        <pub-id pub-id-type="doi">10.1186/1757-2215-6-34</pub-id>
        <?supplied-pmid 23663245?>
        <pub-id pub-id-type="pmid">23663245</pub-id>
      </element-citation>
    </ref>
    <ref id="CR44">
      <label>44.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shijo</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Metastasis of ovarian cancer to the bile duct: a case report</article-title>
        <source>Surg. Case Rep.</source>
        <year>2019</year>
        <volume>5</volume>
        <fpage>100</fpage>
        <pub-id pub-id-type="doi">10.1186/s40792-019-0659-9</pub-id>
        <?supplied-pmid 31222668?>
        <pub-id pub-id-type="pmid">31222668</pub-id>
      </element-citation>
    </ref>
    <ref id="CR45">
      <label>45.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Shen</surname>
            <given-names>TK</given-names>
          </name>
          <name>
            <surname>Teknos</surname>
            <given-names>TN</given-names>
          </name>
          <name>
            <surname>Toland</surname>
            <given-names>AE</given-names>
          </name>
          <name>
            <surname>Senter</surname>
            <given-names>L</given-names>
          </name>
          <name>
            <surname>Nagy</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>Salivary gland cancer in BRCA-positive families: a retrospective review</article-title>
        <source>JAMA Otolaryngol. Head Neck Surg.</source>
        <year>2014</year>
        <volume>140</volume>
        <fpage>1213</fpage>
        <lpage>1217</lpage>
        <pub-id pub-id-type="doi">10.1001/jamaoto.2014.1998</pub-id>
        <?supplied-pmid 25257187?>
        <pub-id pub-id-type="pmid">25257187</pub-id>
      </element-citation>
    </ref>
    <ref id="CR46">
      <label>46.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Chao</surname>
            <given-names>W-T</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Neurofibroma involving obturator nerve mimicking an adnexal mass: a rare case report and PRISMA-driven systematic review</article-title>
        <source>J. Ovarian Res.</source>
        <year>2018</year>
        <volume>11</volume>
        <fpage>14</fpage>
        <pub-id pub-id-type="doi">10.1186/s13048-018-0386-z</pub-id>
        <?supplied-pmid 29426349?>
        <pub-id pub-id-type="pmid">29426349</pub-id>
      </element-citation>
    </ref>
    <ref id="CR47">
      <label>47.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Liang</surname>
            <given-names>L</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Renal cell carcinoma metastatic to the ovary or fallopian tube: a clinicopathological study of 9 cases</article-title>
        <source>Hum. Pathol.</source>
        <year>2016</year>
        <volume>51</volume>
        <fpage>96</fpage>
        <lpage>102</lpage>
        <pub-id pub-id-type="doi">10.1016/j.humpath.2015.12.017</pub-id>
        <?supplied-pmid 27067787?>
        <pub-id pub-id-type="pmid">27067787</pub-id>
      </element-citation>
    </ref>
    <ref id="CR48">
      <label>48.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Brunckhorst</surname>
            <given-names>MK</given-names>
          </name>
          <name>
            <surname>Xu</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Lu</surname>
            <given-names>R</given-names>
          </name>
          <name>
            <surname>Yu</surname>
            <given-names>Q</given-names>
          </name>
        </person-group>
        <article-title>Angiopoietins promote ovarian cancer progression by establishing a procancer microenvironment</article-title>
        <source>Am. J. Pathol.</source>
        <year>2014</year>
        <volume>184</volume>
        <fpage>2285</fpage>
        <lpage>2296</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ajpath.2014.05.006</pub-id>
        <?supplied-pmid 25043619?>
        <pub-id pub-id-type="pmid">25043619</pub-id>
      </element-citation>
    </ref>
    <ref id="CR49">
      <label>49.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lee</surname>
            <given-names>C</given-names>
          </name>
        </person-group>
        <article-title>Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells</article-title>
        <source>Mol. Med. Rep.</source>
        <year>2015</year>
        <volume>12</volume>
        <fpage>1485</fpage>
        <lpage>1492</lpage>
        <pub-id pub-id-type="doi">10.3892/mmr.2015.3542</pub-id>
        <?supplied-pmid 25815442?>
        <pub-id pub-id-type="pmid">25815442</pub-id>
      </element-citation>
    </ref>
    <ref id="CR50">
      <label>50.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Yu</surname>
            <given-names>TT</given-names>
          </name>
          <name>
            <surname>Wang</surname>
            <given-names>CY</given-names>
          </name>
          <name>
            <surname>Tong</surname>
            <given-names>R</given-names>
          </name>
        </person-group>
        <article-title>ERBB2 gene expression silencing involved in ovarian cancer cell migration and invasion through mediating MAPK1/MAPK3 signaling pathway</article-title>
        <source>Eur. Rev. Med. Pharm. Sci.</source>
        <year>2020</year>
        <volume>24</volume>
        <fpage>5267</fpage>
        <lpage>5280</lpage>
      </element-citation>
    </ref>
    <ref id="CR51">
      <label>51.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Jukonen</surname>
            <given-names>J</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Aggressive and recurrent ovarian cancers upregulate ephrinA5, a non-canonical effector of EphA2 signaling duality</article-title>
        <source>Sci. Rep.</source>
        <year>2021</year>
        <volume>11</volume>
        <fpage>8856</fpage>
        <pub-id pub-id-type="doi">10.1038/s41598-021-88382-6</pub-id>
        <?supplied-pmid 33893375?>
        <pub-id pub-id-type="pmid">33893375</pub-id>
      </element-citation>
    </ref>
    <ref id="CR52">
      <label>52.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kurian</surname>
            <given-names>AW</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Association of ovarian cancer (OC) risk with mutations detected by multiple-gene germline sequencing in 95,561 women</article-title>
        <source>J. Clin. Oncol.</source>
        <year>2016</year>
        <volume>34</volume>
        <fpage>5510</fpage>
        <lpage>5510</lpage>
        <pub-id pub-id-type="doi">10.1200/JCO.2016.34.15_suppl.5510</pub-id>
      </element-citation>
    </ref>
    <ref id="CR53">
      <label>53.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Ye</surname>
            <given-names>H</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Primary ovarian angiosarcoma: a rare and recognizable ovarian tumor</article-title>
        <source>J. Ovarian Res.</source>
        <year>2021</year>
        <volume>14</volume>
        <fpage>21</fpage>
        <pub-id pub-id-type="doi">10.1186/s13048-021-00771-7</pub-id>
        <?supplied-pmid 33509230?>
        <pub-id pub-id-type="pmid">33509230</pub-id>
      </element-citation>
    </ref>
    <ref id="CR54">
      <label>54.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>van Niekerk</surname>
            <given-names>CC</given-names>
          </name>
          <name>
            <surname>Bulten</surname>
            <given-names>J</given-names>
          </name>
          <name>
            <surname>Verbeek</surname>
            <given-names>AL</given-names>
          </name>
        </person-group>
        <article-title>Epithelial ovarian cancer and the occurrence of skin cancer in the Netherlands: histological type connotations</article-title>
        <source>ISRN Obstet. Gynecol.</source>
        <year>2011</year>
        <volume>2011</volume>
        <fpage>617082</fpage>
        <?supplied-pmid 21776400?>
        <pub-id pub-id-type="pmid">21776400</pub-id>
      </element-citation>
    </ref>
    <ref id="CR55">
      <label>55.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lech</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Ovarian cancer as a genetic disease</article-title>
        <source>Front. Biosci.</source>
        <year>2013</year>
        <volume>18</volume>
        <fpage>543</fpage>
        <lpage>563</lpage>
        <pub-id pub-id-type="doi">10.2741/4119</pub-id>
      </element-citation>
    </ref>
    <ref id="CR56">
      <label>56.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Kaleli</surname>
            <given-names>S</given-names>
          </name>
          <name>
            <surname>Calay</surname>
            <given-names>Z</given-names>
          </name>
          <name>
            <surname>Ceydeli</surname>
            <given-names>N</given-names>
          </name>
          <name>
            <surname>Aydýnlý</surname>
            <given-names>K</given-names>
          </name>
          <name>
            <surname>Kösebay</surname>
            <given-names>D</given-names>
          </name>
        </person-group>
        <article-title>A huge abdominal mass mimicking ovarian cancer: p53-negative but aneuploid myxoid leiomyosarcoma of the uterus</article-title>
        <source>Eur. J. Obstet. Gynecol. Reprod. Biol.</source>
        <year>2001</year>
        <volume>100</volume>
        <fpage>96</fpage>
        <lpage>99</lpage>
        <pub-id pub-id-type="doi">10.1016/S0301-2115(01)00446-8</pub-id>
        <?supplied-pmid 11728667?>
        <pub-id pub-id-type="pmid">11728667</pub-id>
      </element-citation>
    </ref>
    <ref id="CR57">
      <label>57.</label>
      <mixed-citation publication-type="other">Tanaka, A. et al. Case report of a primary ovarian leiomyosarcoma diagnosed by H-caldesmon staining. <italic>J.Clin. Gynecol. Obstet</italic>. <bold>7</bold>, 26–29 (2018).</mixed-citation>
    </ref>
    <ref id="CR58">
      <label>58.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Macciò</surname>
            <given-names>A</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia</article-title>
        <source>Blood</source>
        <year>2005</year>
        <volume>106</volume>
        <fpage>362</fpage>
        <lpage>367</lpage>
        <pub-id pub-id-type="doi">10.1182/blood-2005-01-0160</pub-id>
        <?supplied-pmid 15774616?>
        <pub-id pub-id-type="pmid">15774616</pub-id>
      </element-citation>
    </ref>
    <ref id="CR59">
      <label>59.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Clinkard</surname>
            <given-names>DJ</given-names>
          </name>
          <name>
            <surname>Khalifa</surname>
            <given-names>M</given-names>
          </name>
          <name>
            <surname>Osborned</surname>
            <given-names>RJ</given-names>
          </name>
          <name>
            <surname>Bouffet</surname>
            <given-names>E</given-names>
          </name>
        </person-group>
        <article-title>Successful management of medulloblastoma arising in an immature ovarian teratoma in pregnancy</article-title>
        <source>Gynecologic Oncol.</source>
        <year>2011</year>
        <volume>120</volume>
        <fpage>311</fpage>
        <lpage>312</lpage>
        <pub-id pub-id-type="doi">10.1016/j.ygyno.2010.10.022</pub-id>
      </element-citation>
    </ref>
    <ref id="CR60">
      <label>60.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hearle</surname>
            <given-names>N</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Contribution of germline mutations in BRCA2, P16 INK4A, P14 ARF and P15 to uveal melanoma</article-title>
        <source>Invest. Ophthalmol. Vis. Sci.</source>
        <year>2003</year>
        <volume>44</volume>
        <fpage>458</fpage>
        <lpage>462</lpage>
        <pub-id pub-id-type="doi">10.1167/iovs.02-0026</pub-id>
        <?supplied-pmid 12556369?>
        <pub-id pub-id-type="pmid">12556369</pub-id>
      </element-citation>
    </ref>
    <ref id="CR61">
      <label>61.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Vaz</surname>
            <given-names>F</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Mutation of the RAD51C gene in a Fanconi anemia-like disorder</article-title>
        <source>Nat. Genet.</source>
        <year>2010</year>
        <volume>42</volume>
        <fpage>406</fpage>
        <lpage>409</lpage>
        <pub-id pub-id-type="doi">10.1038/ng.570</pub-id>
        <?supplied-pmid 20400963?>
        <pub-id pub-id-type="pmid">20400963</pub-id>
      </element-citation>
    </ref>
    <ref id="CR62">
      <label>62.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Futagawa</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Retroperitoneal leiomyosarcoma in a female patient with a germline splicing variant RAD51D c.904-2A &gt; T: a case report</article-title>
        <source>Hered. Cancer Clin. Pract.</source>
        <year>2021</year>
        <volume>19</volume>
        <fpage>48</fpage>
        <pub-id pub-id-type="doi">10.1186/s13053-021-00205-x</pub-id>
        <?supplied-pmid 34838098?>
        <pub-id pub-id-type="pmid">34838098</pub-id>
      </element-citation>
    </ref>
    <ref id="CR63">
      <label>63.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Lorenzo</surname>
            <given-names>D</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Role of endoscopic ultrasound in the screening and follow-up of high-risk individuals for familial pancreatic cancer</article-title>
        <source>World J. Gastroenterol.</source>
        <year>2019</year>
        <volume>25</volume>
        <fpage>5082</fpage>
        <lpage>5096</lpage>
        <pub-id pub-id-type="doi">10.3748/wjg.v25.i34.5082</pub-id>
        <?supplied-pmid 31558858?>
        <pub-id pub-id-type="pmid">31558858</pub-id>
      </element-citation>
    </ref>
    <ref id="CR64">
      <label>64.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <collab>The UniProt, C.</collab>
        </person-group>
        <article-title>UniProt: the universal protein knowledgebase in 2021</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2021</year>
        <volume>49</volume>
        <fpage>D480</fpage>
        <lpage>D489</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkaa1100</pub-id>
        <pub-id pub-id-type="pmid">33237286</pub-id>
      </element-citation>
    </ref>
    <ref id="CR65">
      <label>65.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Klug</surname>
            <given-names>A</given-names>
          </name>
        </person-group>
        <article-title>The discovery of zinc fingers and their applications in gene regulation and genome manipulation</article-title>
        <source>Annu. Rev. Biochem.</source>
        <year>2010</year>
        <volume>79</volume>
        <fpage>213</fpage>
        <lpage>231</lpage>
        <pub-id pub-id-type="doi">10.1146/annurev-biochem-010909-095056</pub-id>
        <?supplied-pmid 20192761?>
        <pub-id pub-id-type="pmid">20192761</pub-id>
      </element-citation>
    </ref>
    <ref id="CR66">
      <label>66.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Irwin</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Shoichet</surname>
            <given-names>BK</given-names>
          </name>
        </person-group>
        <article-title>ZINC-a free database of commercially available compounds for virtual screening</article-title>
        <source>J. Chem. Inf. Model.</source>
        <year>2005</year>
        <volume>45</volume>
        <fpage>177</fpage>
        <lpage>182</lpage>
        <pub-id pub-id-type="doi">10.1021/ci049714+</pub-id>
        <?supplied-pmid 15667143?>
        <pub-id pub-id-type="pmid">15667143</pub-id>
      </element-citation>
    </ref>
    <ref id="CR67">
      <label>67.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hassanzadeh</surname>
            <given-names>O</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Causal knowledge extraction through large-scale text mining</article-title>
        <source>Proc. AAAI Conf. Artif. Intell.</source>
        <year>2020</year>
        <volume>34</volume>
        <fpage>13610</fpage>
        <lpage>13611</lpage>
      </element-citation>
    </ref>
    <ref id="CR68">
      <label>68.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Wishart</surname>
            <given-names>DS</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>
        <source>Nucleic Acids Res.</source>
        <year>2018</year>
        <volume>46</volume>
        <fpage>D1074</fpage>
        <lpage>D1082</lpage>
        <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>
        <?supplied-pmid 29126136?>
        <pub-id pub-id-type="pmid">29126136</pub-id>
      </element-citation>
    </ref>
    <ref id="CR69">
      <label>69.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Zhou</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Cao</surname>
            <given-names>H</given-names>
          </name>
          <name>
            <surname>Skolnick</surname>
            <given-names>J</given-names>
          </name>
        </person-group>
        <article-title>FINDSITE<sup>comb2.0</sup>: a new approach for virtual ligand screening of proteins and virtual target screening of biomolecules</article-title>
        <source>J. Chem. Inf. Model.</source>
        <year>2018</year>
        <volume>58</volume>
        <fpage>2343</fpage>
        <lpage>2354</lpage>
        <pub-id pub-id-type="doi">10.1021/acs.jcim.8b00309</pub-id>
        <?supplied-pmid 30278128?>
        <pub-id pub-id-type="pmid">30278128</pub-id>
      </element-citation>
    </ref>
    <ref id="CR70">
      <label>70.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Fisher</surname>
            <given-names>RA</given-names>
          </name>
        </person-group>
        <article-title>On the interpretation of χ<sup>2</sup> from contingency tables, and the calculation of P</article-title>
        <source>J. R. Stat. Soc.</source>
        <year>1922</year>
        <volume>85</volume>
        <fpage>87</fpage>
        <lpage>94</lpage>
        <pub-id pub-id-type="doi">10.2307/2340521</pub-id>
      </element-citation>
    </ref>
    <ref id="CR71">
      <label>71.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Mehta</surname>
            <given-names>CR</given-names>
          </name>
          <name>
            <surname>Patel</surname>
            <given-names>NR</given-names>
          </name>
        </person-group>
        <article-title>ALGORITHM 643: FEXACT: a FORTRAN subroutine for Fisher’s exact test on unordered r×c contingency tables</article-title>
        <source>ACM Trans. Math. Softw.</source>
        <year>1986</year>
        <volume>12</volume>
        <fpage>154</fpage>
        <lpage>161</lpage>
        <pub-id pub-id-type="doi">10.1145/6497.214326</pub-id>
      </element-citation>
    </ref>
    <ref id="CR72">
      <label>72.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Uhlén</surname>
            <given-names>M</given-names>
          </name>
          <etal/>
        </person-group>
        <article-title>Tissue-based map of the human proteome</article-title>
        <source>Science</source>
        <year>2015</year>
        <volume>347</volume>
        <fpage>1260419</fpage>
        <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
        <?supplied-pmid 25613900?>
        <pub-id pub-id-type="pmid">25613900</pub-id>
      </element-citation>
    </ref>
    <ref id="CR73">
      <label>73.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Goeman</surname>
            <given-names>JJ</given-names>
          </name>
          <name>
            <surname>Bühlmann</surname>
            <given-names>P</given-names>
          </name>
        </person-group>
        <article-title>Analyzing gene expression data in terms of gene sets: methodological issues</article-title>
        <source>Bioinformatics</source>
        <year>2007</year>
        <volume>23</volume>
        <fpage>980</fpage>
        <lpage>987</lpage>
        <pub-id pub-id-type="doi">10.1093/bioinformatics/btm051</pub-id>
        <?supplied-pmid 17303618?>
        <pub-id pub-id-type="pmid">17303618</pub-id>
      </element-citation>
    </ref>
    <ref id="CR74">
      <label>74.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Benjamini</surname>
            <given-names>Y</given-names>
          </name>
          <name>
            <surname>Hochberg</surname>
            <given-names>Y</given-names>
          </name>
        </person-group>
        <article-title>Controlling the false discovery rate: a practical and powerful approach to multiple testing</article-title>
        <source>J. R. Stat. Soc. Ser. B</source>
        <year>1995</year>
        <volume>57</volume>
        <fpage>289</fpage>
        <lpage>300</lpage>
      </element-citation>
    </ref>
    <ref id="CR75">
      <label>75.</label>
      <element-citation publication-type="journal">
        <person-group person-group-type="author">
          <name>
            <surname>Hintzsche</surname>
            <given-names>JD</given-names>
          </name>
          <name>
            <surname>Robinson</surname>
            <given-names>WA</given-names>
          </name>
          <name>
            <surname>Tan</surname>
            <given-names>AC</given-names>
          </name>
        </person-group>
        <article-title>A survey of computational tools to analyze and interpret whole exome sequencing data</article-title>
        <source>Int. J. Genomics</source>
        <year>2016</year>
        <volume>2016</volume>
        <fpage>7983236</fpage>
        <pub-id pub-id-type="doi">10.1155/2016/7983236</pub-id>
        <?supplied-pmid 28070503?>
        <pub-id pub-id-type="pmid">28070503</pub-id>
      </element-citation>
    </ref>
    <ref id="CR76">
      <label>76.</label>
      <mixed-citation publication-type="other">NCI-60 human tumor cell lines screen. <ext-link ext-link-type="uri" xlink:href="https://dtp.cancer.gov/discovery_development/nci-60/">https://dtp.cancer.gov/discovery_development/nci-60/</ext-link>.</mixed-citation>
    </ref>
  </ref-list>
</back>
